Late effects of adjuvant chemotherapy on brain function and structure by Koppelmans, V. (Vincent)


Late Effects of Adjuvant Chemotherapy 
on Brain Function and Structure
Vincent Koppelmans
# H0-Titel Pagina 20120217.indd   1 23-02-12   15:58
Acknowledgements
Cover design: Stefanie de Blank
Thesis layout: Vincent Koppelmans
Printed by: Optima Grafische Communicatie
The work described in this thesis was conducted at the Department of Epidemiology of 
the Erasmus University Medical Center, Rotterdam, the Netherlands and the Division of 
Psychosocial Oncology and Epidemiology of the Netherlands Cancer Institute / Antoni van 
Leeuwenhoek Hospital, Amsterdam, the Netherlands. 
The research described in this thesis was supported by a grant from the Dutch Cancer Society 
(2007-3797) to S.B. Schagen and M.M.B. Breteler. The Rotterdam Study is supported by the 
Erasmus University Medical Center and Erasmus University Rotterdam, the Netherlands 
Organization for Scientific Research (NWO), the Netherlands Organization for Health Research 
and Development (ZonMW), the Research Institute for Diseases in the Elderly (RIDE), the 
Ministry of Education, Culture and Science, the Ministry of Health, Welfare and Sports, the 
European Commission (DG XII), and the Municipality of Rotterdam.
Financial support for the publication of this thesis was kindly provided by the Department of 
Epidemiology of the Erasmus University Medical Center, Rotterdam; the Erasmus University 
Rotterdam, Alzheimer Nederland, Lundbeck BV, Boehringer Ingelheim BV, and the Dutch 
Cancer Society.
ISBN: 978-94-6050-007-7 
© V. Koppelmans, 2012
All rights reserved. No part of this thesis may be reproduced in any form or by any means 
without written permission from the author.
# H0-Titel Pagina 20120217.indd   2 23-02-12   15:58
Late Effects of Adjuvant Chemotherapy 
on Brain Function and Structure
Late effecten van adjuvante chemotherapie op het 
functioneren en de structuur van de hersenen
Proefschrift
ter verkrijging van de graad van doctor aan de 
Erasmus Universiteit Rotterdam 
op gezag van de rector magnificus
Prof.dr. H.G. Schmidt
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
vrijdag 20 april 2012 om 09:30 uur
door
Vincent Kopppelmans
geboren te Eindhoven
# H0-Titel Pagina 20120217.indd   3 23-02-12   15:58
Promotiecommissie:
Promotor: Prof.dr. M.M.B. Breteler
Overige leden: Prof.dr. A. van der Lugt
  Prof.dr. M.J. van den Bent
  Prof.dr. F.D. Grodstein
Copromotor: Dr. S.B. Schagen
# H0-Titel Pagina 20120217.indd   4 23-02-12   15:58
Contents
Chapter 1 General Introduction 7
Chapter 2 Review: Late effects of adjuvant chemotherapy for adult onset 
non-CNS cancer; cognitive impairment, brain structure and 
risk of dementia
21
Chapter 3 Neuropsychological performance in breast cancer survivors 
more than 20 years after adjuvant chemotherapy
51
Chapter 4 Late effects of chemotherapy on brain structure 69
Chapter 4.1 Global and focal brain volume in long-term breast cancer 
survivors exposed to adjuvant chemotherapy
71
Chapter 4.2 Global and focal white matter integrity in breast cancer 
survivors 20 years after adjuvant chemotherapy
85
Chapter 4.3 Long-term effects of adjuvant chemotherapy for breast cancer 
on carotid artery plaques, cerebral blood flow and cerebral 
perfusion
103
Chapter 5 Incidental findings on brain Magnetic Resonance Imaging in 
long-term survivors of breast cancer treated with adjuvant 
chemotherapy
117
Chapter 6 General Discussion 129
Chapter 7 Summary / Samenvatting
Dankwoord
List of publications
PhD Portfolio
151
161
167
169
# H0-Titel Pagina 20120217.indd   5 23-02-12   15:58
# H0-Titel Pagina 20120217.indd   6 23-02-12   15:58
Chapter 1
General Introduction
O
OH
HN O
OH
O
N
N
N
N
N
H
2
N
NH
2
# H1-Introductie 20120215b.indd   7 23-02-12   16:03
# H1-Introductie 20120215b.indd   8 23-02-12   16:03
9Late effects of adjuvant chemotherapy on brain function and structure
C
hapter 1
Trends in breast cancer incidence, mortality and survival
Breast cancer is the most frequent malignancy in women in Western Europe and the United 
States. In 2009, 13,177 new cases of breast cancer were diagnosed within the Netherlands 
alone (1). The lifetime risk of breast cancer in Dutch women reached 1 in 8.3 between 2005 and 
2009 (1), which is comparable to the lifetime risk of 1 in 8.2 in United States women that was 
observed between 2005 and 2007 (2). 
The European Standardized Rates of breast cancer in the Netherlands significantly increased 
from 97.4 per 100,000 in 1989 to 129.6 per 100,000 in 2007 (1). This increase has been ascribed 
to lifestyle changes such as delayed childbearing, lower parity, reduced breast-feeding and 
increased body-mass index (3-6). At the same time, mortality rates have decreased slightly as 
a result of improved treatment and possibly as a result of population screening (7-9). Because of 
the increased incidence and slightly decreased mortality, the number of survivors has increased 
(8). 
Chemotherapy and cognitive functioning
Adjuvant chemotherapy for breast cancer is given in addition to the primary loco-regional 
treatment and aims to eliminate occult micro-metastases. Nowadays, 60% of the newly 
diagnosed breast cancer patients younger than 65 years of age receive chemotherapy, although 
only about half of them benefit from it (10). To identify those patients that are likely to profit 
from cytotoxic treatment, the patients risk profile of metastasis is determined on the basis of 
tumor size and grade, age, number of positive lymph nodes and tumor receptor status (11). In 
addition, the use of gene-expression profiles can be used to distinguish between patients with a 
favorable and an unfavorable prognosis and to predict cytotoxic treatment response (11). This 
is important as chemotherapy can induce various adverse reactions such as nausea, hair loss 
and fatigue. A less known side effect of chemotherapy that has been increasingly studied over 
the last decade is cognitive dysfunction (12). 
Initial studies on the potential effect of chemotherapy on cognitive functioning were conducted 
in the early nineties following patients complaints of impaired cognition after conventional 
cytotoxic treatment (13). Since then, cognitive problems after chemotherapy have been 
recognized by patients who often refer to them as “chemobrain”. Besides the work reported in 
this thesis, 41 studies have investigated the effects of chemotherapy on cognitive functioning 
in breast cancer patients (13-53). Of these studies, 19 were cross-sectional (see Figure 1) and 
23 had prospective designs (see Figure 2). Of the 41 studies, 27 (66%) reported significant 
adverse effects of chemotherapy on cognitive functioning, mainly in the domains of information 
processing speed and memory (12). The remaining 13 studies reported no significant adverse 
effect or no effect of cytotoxic treatment. No studies reported a positive effect of chemotherapy 
on cognitive functioning. The adverse cognitive effects of chemotherapy have been observed 
during, shortly and up till 16 years after various conventional and high-dose cytotoxic regimens. 
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A meta-analysis revealed that effect sizes of studies on chemotherapy-induced cognitive 
dysfunction varied from small to moderate (-0.07 to -0.50) (54). Chemotherapy-induced 
cognitive dysfunction has been almost exclusively been studied in Caucasian samples, except 
for a few studies in Japanese women (25, 31). Therefore, not much is known about whether 
this problem is similar in size and in other populations. Some prospective studies with pre-
chemotherapy assessments reported that breast cancer patients already performed worse on 
neuropsychological tests before cytotoxic treatment than non-cancer controls (21, 40). Follow-
up measurements however showed deterioration of cognitive functioning after chemotherapy, 
indicating that the adverse cognitive effect observed in chemotherapy-exposed patients is at 
Figure 1. Time since treatment in relation to the number of chemotherapy-exposed patients 
in cross-sectional studies on the effects of chemotherapy on cognitive functioning.
Figure 2. Time since treatment in relation to the number of chemotherapy-exposed patients 
in prospective studies on the effects of chemotherapy on cognitive functioning.
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least partly due to the cytotoxic treatment and not only a result of the possible effect of cancer 
itself (48). Various studies have investigated whether cancer related mood disorders and fatigue 
are associated with cognitive dysfunction, but no strong evidence has been observed for such 
a relationship (55). Fatigue and mood disorders after cancer diagnosis and treatment have 
been related to subjective cognitive complaints, which also do not predict objective cognitive 
functioning (12, 56). Animal models have offered a good opportunity to investigate the effects of 
single cytotoxic agents and avoid the potential cancer and treatment related psychological effects 
on cognition (57). These studies showed that single common agents such as cyclophosphamide 
and methotrexate can induce memory problems in rodents (58-60). Of important notice is that 
not all patients who receive chemotherapy encounter cognitive side effects of chemotherapy. 
Across studies, the proportion of patients with cognitive dysfunction following chemotherapy 
ranges from 13-70% (56). Putative explanations for the large differences in proportion between 
studies include the different cytotoxic regimens under investigation, differences in the mean 
time since treatment, the diverse neuropsychological test batteries, the various definitions 
of cognitive impairment and change cognitive functioning, and the use of different reference 
groups or reference data that are used.
Besides our research, only four other studies have investigated these adverse effects five or 
more years post-treatment (17, 29, 49, 50). Although the results of these studies suggest that 
chemotherapy is associated with long-term cognitive functioning, they all had cross-sectional 
designs and small sample sizes. Therefore the long-term relationship between chemotherapy 
and cognitive functioning remains largely unknown. 
Mechanisms for chemotherapy-induced cognitive dysfunction
Little is known about the mechanisms that underlie chemotherapy-induced cognitive 
dysfunction (61). Chemotherapy may have a direct neurotoxic effect on central nervous system 
cells. Depending on the frequency of administration, prescribed dosage, administration route, 
and whether or not given in combination with radiotherapy, certain cytotoxic agents are able 
to cross the blood brain barrier in substantial amounts (62). Examples of such agents that have 
long been prescribed and are still applied in the adjuvant treatment for breast cancer include 
methotrexate and 5-fluorouracil (63, 64). By entering the brain parenchyma, cytotoxic agents 
may cause seizures, cerebellar dysfunction, extrapyramidal disorders and cognitive dysfunction 
(62). Animal studies support these findings by showing that several single agents such as 
methotrexate and cyclophosphamide that are administered peripherally in clinically relevant 
dosages are associated with reduced neurogenesis, apoptosis, oxidative stress, (delayed) white 
matter damage, and learning disabilities (57, 65, 66). 
Furthermore, chemotherapy has been associated with DNA damage, increased rate of 
telomere shortening, and increased oxidative stress (67), which subsequently could lead to 
cognitive dysfunction. Other proposed mechanisms include cardio-toxicity, which may affect 
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cognitive functioning through effects on cerebrovascular integrity. Because central nervous 
system regeneration is limited (68, 69), it is possible that chemotherapy-induced cognitive 
dysfunction is persistent rather than transient. 
In the general population cognitive dysfunction has been associated with brain structural 
changes such as global and focal gray matter volume (70), white matter lesions (71), and 
reduced microstructural integrity of the normal appearing white matter (72-74). The relationship 
between chemotherapy, cognitive functioning and brain structural alterations is yet largely 
unknown but not unlikely considering that under certain conditions some cytotoxic agents can 
penetrate the blood brain barrier. Besides our own study, twelve imaging studies, of which 
two had a prospective design and ten had cross-sectional designs, have been conducted in 
chemotherapy-exposed patients. These studies showed that shortly up till approximately 
three years post-treatment, chemotherapy is associated with brain structural changes, mainly 
detectable as white matter hyperintensities (75-77), lower quality of white matter (32, 51), and 
gray matter volume reductions (78). Even though chemotherapy-induced brain alterations 
seem to be at least partially transient (31, 76, 78), the only study that examined the association 
between chemotherapy and brain structure in patients almost ten years post-treatment 
showed focal effects of chemotherapy on white matter quality and gray matter (79). The idea 
that chemotherapy is associated with long-term brain structural alterations is strengthened by 
animal studies in which delayed myelin destruction of the central nervous system and long-
lasting suppression of hippocampal cell proliferation were observed in rodents that had received 
clinically relevant doses of cyclophosphamide and methotrexate (59, 65). 
Scope of the thesis
With the steeply increasing number of long-term breast cancer survivors who are aware of 
the potential cognitive side effects of cytotoxic systemic therapy, there is need for clarification 
on the potential long-term cognitive effects of chemotherapy that can adversely affect quality of 
life (80). Results from the few small studies on the late effects of chemotherapy on either brain 
function or structure suggest that these effects may not be transient. These outcomes warrant 
the investigation of the late effects of chemotherapy through large-scale studies that combine 
imaging, neuropsychological testing, and questionnaires on subjective cognitive complaints. In 
this thesis I will try to answer the question if standard-dose adjuvant chemotherapy for breast 
cancer is associated with long-term cognitive functioning and brain structure. 
Breast cancer survivors and reference subjects from the general population
The studies described in this thesis are all based on data from almost 200 chemotherapy-
exposed breast cancer survivors who have been treated with CMF (Cyclophosphamide, 
Methotrexate, 5-Fluorouracil) chemotherapy at the Netherlands Cancer Institute/Antoni van 
Leeuwenhoek Hospital or the Daniel den Hoed Cancer Clinic, on average more than 20 years 
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Figure 3. Positioning of the current study among published cross-sectional studies on the 
late effects of chemotherapy on cognitive functioning
ago. 
A reference group of non-exposed control subjects who had never been diagnosed with 
cancer was sampled from the Rotterdam Study (RS). The Rotterdam Study is a population 
based cohort study that is ongoing since 1990 in the Ommoord district in Rotterdam, the 
Netherlands. Ever since its start the study has included almost 15,000 subjects who are invited 
for follow-up examinations every three to four years. Amongst many others, examinations 
include questionnaires on medical history, mood, and subjective cognitive functioning, 
neuropsychological testing, MRI examination and carotid artery ultrasound. 
Breast cancer survivors were assessed at the research center of the Rotterdam Study in 
exactly the same way as the reference subjects following the protocol of the Rotterdam Study. 
By sampling a population-based reference group from an existing study we were able to 
put all our effort and resources into including a large number of chemotherapy-exposed breast 
cancer survivors. The large number of subjects and the extensive set of examinations enabled 
us to adjust for several confounders and detect even small effects. Figure 3 shows how the 
current study relates to other cross-sectional studies that have been published regarding 
sample size and mean time since treatment.
Thesis outline
In Chapter 2 I give an overview of the few studies that have investigated the effects of 
chemotherapy in subjects who completed treatment for breast cancer five or more years before 
and studies that have looked at the risk of dementia after cytotoxic treatment. 
Chapter 3 reports on the outcome of our study on the effects of chemotherapy on cognition 
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in long-term breast cancer survivors. To investigate this effect we compare neuropsychological 
test outcomes of breast cancer survivors who have been treated with standard-dose CMF 
chemotherapy to neuropsychological test outcomes of a population-based sample of women 
from the general population who were never diagnosed with cancer. 
In Chapter 4 the association between CMF chemotherapy and long-term brain structure is 
discussed. Chapter 4.1 focuses on the relation between cytotoxic treatment and brain volume, 
gray matter volume, white matter volume and hippocampal volume. Subsequently the effect 
of chemotherapy on local gray matter density is explored using Voxel Based Morphometry 
(VBM). In Chapter 4.2 I relate chemotherapy and time since treatment to global and local white 
matter quality using Diffusion Tensor Imaging (DTI) and Tract Based Spatial Statistics (TBSS). 
Chapter 4.3 reports on the association between chemotherapy, carotid artery integrity and 
cerebral blood flow and brain perfusion. In Chapter 5 I describe the relative risks of incidental 
findings on brain MRI for breast cancer survivors, who completed chemotherapy on average 
more than 20 years ago, in relation to the risk of incidental findings in the general population. 
Finally, in Chapter 6 I summarize the late-effects of CMF chemotherapy for breast cancer on 
cognition and brain structure, and I discuss implications and suggestions for future research.
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Abstract
Purpose: Adjuvant chemotherapy for breast cancer can have adverse effects on cognition 
shortly after administration. Whether chemotherapy has any long-term effects on cognition 
is largely unknown, yet becomes increasingly relevant because of the widespread use of 
chemotherapy for early breast cancer and the improved survival. We investigated whether 
CMF chemotherapy for breast cancer is associated with worse cognitive performance more 
than 20 years after treatment.
Methods: Case-cohort study comparing the cognitive performance of breast cancer 
patients with a history of adjuvant CMF chemotherapy treatment (six cycles; average time since 
treatment 21 years) (n=196) to that of a population-based sample of women never diagnosed 
with cancer (n=1509). Participants were between 50 and 80 years of age. Exclusion criteria were: 
ever use of adjuvant endocrine therapy, secondary malignancy, recurrence and/or metastasis. 
Results: The chemotherapy-exposed women performed significantly worse than the 
reference group on cognitive tests of immediate (p=.015) and delayed verbal memory 
(p=.002), processing speed (<.001), executive functioning (p=.013) and psycho-motor speed 
(p=.001). They experienced less symptoms of depression (p<.001) yet had significantly more 
memory complaints on two out of three measures that could not be explained by cognitive test 
performance.
Conclusion: Breast cancer survivors treated with adjuvant CMF chemotherapy more than 
20 years ago, perform on average worse on neuropsychological tests than random population 
controls. The pattern of cognitive problems is largely similar to that observed in patients shortly 
after cessation of chemotherapy. This study suggests that cognitive deficits following breast 
cancer diagnosis and subsequent CMF chemotherapy can be long-lasting. 
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Introduction
Chemotherapy has well-recognized acute side-effects, including nausea and hair-loss. 
Cognitive impairment is a potential short-term side effect that has gained more attention only in 
the last decade (1-20). A number of studies have shown that chemotherapy can induce cognitive 
changes up to five years after treatment (2, 5, 14 ,20). Differences are mainly observed in the 
domains of memory, processing speed and executive function and are generally not explained 
by socio-demographic and clinical variables (21). Nevertheless, cognitive dysfunction has also 
been observed in the domains of visuo-spatial functioning (22) and psycho-motor speed (15). 
Potential predictors for cognitive problems in chemotherapy-exposed breast cancer patients, 
such as cognitive reserve and genetic susceptibility, are topics of ongoing research (23). 
Besides differences in cognitive performance, structural brain differences have been observed 
in patients who underwent chemotherapy compared to control subjects, including more white-
matter hyperintensities and microstructural damage to white-matter tracts, and gray matter 
alterations (1, 7, 24-30), whereas functional magnetic resonance imaging (fMRI) studies 
revealed measurable differences in task-specific responsiveness between chemotherapy-
exposed patients and control subjects (5, 26, 31). The observational studies in humans are 
strongly supported by animal studies (32).
Whether chemotherapy has long-term effects on brain function is still largely unknown.
However, this question is becoming increasingly relevant as the number of long-term 
survivors is rapidly increasing.
We aimed to investigate the late effects of chemotherapy on cognitive functioning by 
comparing the neuropsychological test performance of women who received adjuvant CMF 
chemotherapy for breast cancer patients on average more than 20 years before with that of a 
population sample of women who had never been diagnosed with cancer.
Materials & methods
Participants
Our case group consisted of breast cancer survivors who had undergone adjuvant 
chemotherapy in either of two specialised cancer clinics in the Netherlands. The reference 
group was selected from an ongoing population study in the Netherlands. The review boards of 
the participating institutes (the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital 
and the Erasmus University Medical Center) approved this study.
Chemotherapy-exposed subjects
From the registries of the Antoni van Leeuwenhoek Hospital/Netherlands Cancer Institute 
and the Erasmus University Medical Center-Daniel den Hoed Cancer Center we identified 
consecutive female breast cancer patients who, as part of their primary treatment had received 
six cycles of adjuvant CMF chemotherapy (Cyclophosphamide 100 mg/m2, taken orally, on days 
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1-14, Methotrexate 40 mg/m2, given intravenously, on days 1 and 8, 5-Fluorouracil 600 mg/
m2, given intravenously, on days 1 and 8) between 1976 and 1995. Eligibility criteria included 
age between 50 and 80 years at recruitment time in 2008, and sufficient command of the Dutch 
language. Only those women who never had a relapse, secondary primary tumour or distant 
metastasis were selected. Exclusion criteria were ever use of adjuvant endocrine therapy and 
contra-indications for MRI.
Potential participants (n=359) were sent an invitation letter and information on the study. 
Twenty patients (5.6%) could not be reached either because their current address was 
unavailable, or they did not react to the invitation or subsequent reminders. Fifteen subjects 
(4.2%) had a health related contra-indication for MRI, 30 (8.4%) were ineligible for MRI-
assessment because of claustrophobia and two (0.6%) patients had insufficient command of the 
Dutch language. The final number of eligible patients was 292 of whom 196 (67.1%) eventually 
agreed to participate and provided written informed consent. Examinations were performed 
between October 2008 and October 2009.
Main reasons for decline were: not wanting to be reminded of the cancer episode (21.9%) 
and unwillingness to undergo MRI-assessment (26.0%). Decliners were older than participants 
(F
1,290
)=12.24; p=.001.
To assess possible selection bias, eligible women who declined participation and women for 
whom claustrophobia was the only contra-indication were invited to complete the interview 
and the neuropsychological assessments at home. Test results of these ‘initial decliners’ were 
compared with the results of those who participated in the current study. Of the 126 invited 
initial decliners (96 decliners + 30 claustrophobic women) 48 (38.1%) agreed to participate. They 
were assessed between November 2009 and June 2010.
Reference group
A reference group was selected from the Rotterdam Study, a population-based prospective 
cohort study ongoing since 1990 in the city of Rotterdam, the Netherlands (33). By the end of 
2008, 14,926 subjects had been included in three separate subcohorts. Rotterdam Study-III 
is the most recent subcohort, which comprises 3932 persons who have been assessed only 
once, namely between February 2006 and December 2008. To date it is the only cohort that is 
assessed with an extensive set of neuropsychological tests and therefore the most appropriate 
reference subcohort. 
From Rotterdam Study-III we selected all women without a history of cancer, based on self-
reports and linkage with data from the general physician, who were between 50 and 80 years 
of age at the time of neuropsychological assessment. In total 1509 subjects met these criteria.
Methods
Examination of the participants took place at the Rotterdam Study research center (34). 
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Participants underwent neuropsychological examinations and an interview identical to those 
used in the Rotterdam Study. Subsequently blood was drawn, height and weight were 
measured, and participants underwent MRI of the brain, carotid ultrasound imaging and an 
electro-cardiogram. Results from the latter measures will be described separately.
Neuropsychological examination
Seven neuropsychological tests were administrated and scored by experienced test-
assistants from the Rotterdam Study. These tests yielded 17 outcomes in the following cognitive 
domains: processing speed, verbal learning, memory, inhibition and word fluency as elements 
of executive functioning, visuo-spatial ability and psycho-motor speed. In addition, the MMSE 
was included as a dementia screener. For an overview of the tests and domains see Table 1 
(35-42). 
Interview
Participants completed an interview on clinical and socio-demographic factors, which 
included questions regarding medical history of neurological, psychiatric and cardiovascular 
diseases. Depressive symptoms were assessed with the Center for Epidemiologic Studies 
Depression scale (CES-D) (43) which was converted to a sum-score according to the standard 
scoring rules (44). Subjective memory complaints were measured with three ‘yes/no’ questions: 
1) Do you have more problems remembering things than before?; 2) Has there been an increase 
in the times that you forgot what you were up to?; 3) Do you have more word finding problems 
than before? Subsequently, participants were asked whether these problems had an acute 
onset (yes/no) and if the severity of the problems had changed over time (no change/problems 
increased/problems decreased). 
Statistical analysis
We compared differences in socio-demographic variables between groups by means 
of binary, ordinal and multinomial logistic regression analysis. Group differences in 
neuropsychological performance and depressive symptoms were investigated with analysis 
of covariance (ANCOVA), adjusted for age, and education. Although studies on the cognitive 
effects of chemotherapy shortly after treatment do not show a strong relationship between 
depressive symptoms and neuropsychological performance, (45) no information is available 
on this potential association long after chemotherapy. Therefore we subsequently adjusted our 
analyses for CES-D sum-score. We used Bonferroni correction to account for multiple testing. 
The age distribution of the reference group was more skewed towards younger ages than 
that of the chemotherapy-exposed cancer survivors. To check whether any residual confounding 
by age remained after standard adjustment for age, we additionally executed all analyses 
1) with propensity scores for age; and 2) using an age-matched reference group randomly 
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drawn from the total 
reference group. Since these 
additional analyses yielded 
similar results as the primary 
analyses, their results are not 
separately reported.
Even though the different 
cognitive tests in our battery 
intend to measure different 
domains, an individual’s 
scores on cognitive tests are 
often related. To account for 
this interdependency between 
test scores, we calculated 
for each individual the 
Mahalanobis Distance (MD) 
(46) as a summary measure 
of overall performance (47). 
The MD takes into account 
the correlations between 
test scores and the different 
variances of the test scores 
and can be interpreted as the 
distance to the mean of the 
multidimensional distribution 
of the neuropsychological 
test scores of the reference 
subjects.
MD was based on all 
tests, except for the Design 
Organization test because 
few women from the 
reference group completed 
this test, and except for the 
MMSE as it is a dementia 
screener. We calculated 
age, education and CES-D 
score adjusted residuals of 
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the neuropsychological tests while the computation of the relevant means and (co)variances 
was based on the residuals of the reference group (47, 48). We assigned a value of zero to all 
residual scores greater than their respective mean score of the reference group such that a 
positive test score(s) could not compensate for negative scores (49). We transformed the MD 
with log base 2 because of skewness of its distribution and subsequently used one-way ANOVA 
to compare MD between the chemotherapy-exposed subjects and the reference group. 
Spearman rank correlation coefficients with 2-sided p-values were calculated to obtain the 
associations between memory complaints, neuropsychological test outcomes and mood. Alpha 
levels were set at p=0.05 for all analyses.
Results
Table 2 presents the baseline characteristics of the chemotherapy-exposed breast cancer 
patients and the reference group. On average, breast cancer survivors were older and had 
completed a higher level of education. They had been diagnosed on average at age 42.9, and 
received chemotherapy on average 21.2 years before enrollment in this study. No differences 
were observed in the prevalence of neurologic, psychiatric or cardiovascular diseases.
Table 2. Socio-demographic and clinical characteristics of former breast cancer patients 
exposed to chemotherapy and the reference group from the general population
Chemotherapy-
exposed patients 
(n=196)
Reference group
(n=1509)
p-value
Mean age in years (Sd) 64.1 (6.4) 57.9 (5.4) <.001
Education level % <.001
primary education 8.7 12.5
lower vocational education 16.3 21.5
intermediate general education 20.4 24.2
intermediate vocational education 16.8 16.3
higher general education 5.6 5.2
college education 23.5 16.1
university education 8.7 4.2
Mean age at BC diagnosis (Sd) 42.9 (5.3)
Mean time since BC diagnosis in years (Sd) 21.2 (4.4)
BC= breast cancer; Sd= Standard deviation.
Neuropsychological outcomes
On all neuropsychological tests chemotherapy-exposed breast cancer survivors performed 
similar or worse than reference subjects. These differences were significant for nearly all trials 
of immediate and delayed recall of the 15WLT, for the color-card and the color-word card of 
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the Stroop test, and for non-dominant-hand performance on the Purdue pegboard test (Table 
3). After Bonferroni corrections, differences on the 15WLT delayed recall, the Stroop color-card 
and the Purdue pegboard test for the non-dominant-hand condition remained significant. MMSE 
scores did not differ between groups. Excluding participants with neurologic or psychiatric 
diseases did not change the outcome of the analyses. 
The base-2-log of the Mahalanobis distance was significantly larger for chemotherapy-
exposed survivors (mean=2.8; sd=2.6) than for the reference group (mean=2.2; sd=2.8; 
((F
1,1648
)=7.3; p=.007) indicating that the former had worse overall cognitive performance. 
Time since diagnosis was not associated with neuropsychological performance in 
chemotherapy-exposed survivors.
Table 4. Subjective cognitive complaints in chemotherapy-exposed breast cancer patients 
and a reference group from the general population
Chemotherapy-
exposed patients
Reference group 95% c.i. for 
OR *
Memory complaints % * % * OR Lower Upper p
More problems remembering a 52.8 46.1 1.32 .96 1.82 .09
Forgetting (daily) pursuits b 42.9 35.2 1.41 1.01 1.96 .042
Word finding problems c 38.2 30.2 1.46 1.04 2.05 .030
Rapid onset of problems d 10.7 13.4 .76 .36 1.62 .48
Change in problems e
worsened over time f 30.5 19.6 1.68 .99 2.82 .05
improved over time f 5.8 6.5 .98 .36 2.65 .97
c.i.= confidence interval; OR= Odds Ratio; * depression score (CES-D depression inventory) 
and age adjusted; a Do you have more problems remembering things than before?; b Has 
there been an increase in the times that you forgot what your were up to?; c Do you have 
more word finding problems than before?; d Did the problems occur suddenly?; e Have the 
problems changed over time?; f Reference category=no change over time. 
Depressive symptoms and memory complaints
The reference group reported significantly more depressive symptoms than the 
chemotherapy-exposed breast cancer survivors (age-adjusted mean sum-score on the 
CESD=6.7, sd=8.4 versus 4.7, sd=8.0; (F
1,1696
)=9.54; p=.002). There was a low correlation 
between memory complaints and total score on the CES-D (ρ=.275; p=<.001) in chemotherapy-
exposed survivors.
The proportion of subjects who reported problems with remembering did not differ between 
groups, yet chemotherapy-exposed breast cancer survivors were more likely to report an 
increase in word finding problems and in the frequency of forgetting pursuits (Table 4). These 
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subjective memory complaints were not related to neuropsychological performance.
Chemotherapy-exposed breast cancer survivors who participated at the research center of 
the Rotterdam Study did not differ from participants who declined participation at the research 
center, but agreed to cognitive testing in their own home regarding age, education level, 
Bonferroni-corrected cognitive scores or mood status. Without correction for multiple testing, 
home participants performed worse than center participants on one out of the seventeen 
cognitive measures, namely the word card of the Stroop test (p=.011).
Discussion
To our knowledge, this is the first report on the cognitive effects of adjuvant CMF chemotherapy 
in breast cancer survivors who completed this treatment on average more than 21 years 
before. Compared to women from the general population without cancer, chemotherapy-
exposed breast cancer survivors performed worse on cognitive tests covering the domains 
of learning, immediate and delayed verbal memory, information processing speed, inhibition 
and psychomotor speed. No differences were observed in scores on a dementia screener. 
The results persisted after controlling for several confounders including age, education-level 
and depression score. After subsequent correction for multiple comparisons, chemotherapy-
exposed survivors still performed worse on tests measuring delayed verbal memory, processing 
speed and psychomotor speed. Also on a summary measure of the neuropsychological tests 
that takes correlations between multiple measures into account, chemotherapy-exposed 
survivors performed significantly worse than women from the general population.
Further, chemotherapy-exposed breast cancer survivors more often reported memory 
complaints, which were not associated with test performance, but were weakly correlated with 
mood. Chemotherapy-exposed survivors had less depressive symptoms than the reference 
group although both groups scored below the cut-off score of 16, indicative for clinical 
depression (43).
Strengths of our study are the large sample size, the long interval since chemotherapy, 
the homogeneous study population regarding cytotoxic agents (regimen, cycles), and the 
large population-based reference group without cancer. Possible selection bias within the 
chemotherapy-exposed group has been investigated, and was found to be unlikely.
We compared chemotherapy-exposed breast cancer survivors to a population-based sample 
of healthy control subjects without a history of cancer because we wanted to investigate to 
which extent chemotherapy-exposed breast cancer survivors deviate from the norm regarding 
cognitive functioning. Subsequently, as tamoxifen was not part of standard treatment in the 
Netherlands until the mid nineteen-nineties, it was not possible to include a comparison group of 
long-term tamoxifen-exposed survivors. Because of our design, we were unable to distinguish 
the effect of chemotherapy on cognition from the possible effect of breast cancer itself.
It has been suggested that breast cancer patients may already do worse on tests of cognitive 
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function compared to healthy controls before the start of chemotherapy (8-10, 15, 18, 50, 51). 
Since we do not have pre-treatment assessments to adjust our results for, our findings might 
partially reflect group differences already present before chemotherapy. The mechanisms for 
pre-treatment differences are largely unknown, although the prevalence of cognitive problems 
at baseline has been associated with breast-cancer stage (51). Suggested explanations for 
pre-treatment problems include diminished cognitive reserve, stimulation of proinflammatory 
cytokines (18), and the effect of anesthetic drugs received for breast surgery (52). Because 
the effect of anesthesia is transient (52) we consider its influence on cognition more than 20 
years post treatment unlikely. Moreover, follow-up studies demonstrated a larger prevalence 
of cognitive decline from baseline in chemotherapy-exposed patients than patients who only 
underwent loco-regional therapy, indicating that at least a part of the deficits are indeed 
associated with cytotoxic treatment (3, 15, 53-56). 
Although information on hormone replacement therapy was not available, we do not think 
this can have majorly confounded our findings as the use of HRT in the Netherlands tended to 
be low in the years under study (<2.5% of women aged 40-74) (57).
An important question is to what extent our observations extent to other chemotherapy 
regimens. The CMF regimen is no longer the most optimal adjuvant chemotherapy for early 
breast cancer. However, it has been the standard regimen up to the nineteen-nineties, and it 
is the only regimen that enables the investigation of the very late effects of chemotherapy in 
sufficiently large numbers of subjects. In addition, there is still an elaborate group of women 
that has been treated with CMF in the late nineties of whom some may experience its cognitive 
side effects in the future. Furthermore, cyclophosphamide and 5-fluorouracil continue to be 
incorporated in currently used regimens for early breast cancer. Even if the findings of our study 
would be specific to CMF, they therefore remain relevant.
Several studies have found impairments in cognitive domains in cancer patients shortly after 
treatment with chemotherapy (4, 58-65). Impairments frequently observed in chemotherapy-
exposed breast cancer patients are learning problems and deficits in memory retrieval with 
more preserved retention, as well as problems with information-processing speed and more 
complex aspects of attention. Imaging studies showed that some chemotherapy regimens may 
induce structural brain alterations (1, 7, 24, 25, 27, 28).
The current study resembles this pattern: chemotherapy-exposed breast cancer survivors 
from our study also had more problems with learning and memory retrieval while retention was 
intact. The combination of worse processing speed, inhibition problems and problems with fine 
motor functioning we observed in chemotherapy-exposed survivors adds to this profile. This 
profile is suggestive for disruption of the frontal-subcortical network and matches the profile 
observed in other studies (65).
The fact that chemotherapy-exposed breast cancer survivors performed worse on the non-
dominant condition of the Purdue pegboard test, but not on the dominant condition, has been 
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Abstract
Introduction: A limited number of studies have associated adjuvant chemotherapy with 
structural brain changes. These studies had small sample sizes and were conducted shortly after 
cessation of chemotherapy. Results of these studies indicate local gray matter volume decrease 
and an increase in white matter lesions. Up till now, it is unclear if non-CNS chemotherapy is 
associated with long-term structural brain changes. We compared focal and total brain volume 
of a large set of non-CNS directed chemotherapy-exposed breast cancer survivors, on average 
21 years post-treatment, to that of a population-based sample of women without a history of 
cancer. 
Methods: Structural MRI (1.5T) was performed in 184 chemotherapy-exposed breast 
cancer patients, mean age 64.0 (sd=6.5) years, who had been diagnosed with cancer on 
average 21.1 (sd=4.4) years before, and 368 age-matched cancer-free reference subjects from 
a population-based cohort study. Outcome measures were: total brain volume and total gray 
and white matter volume, and hippocampal volume. In addition, voxel based morphometry was 
performed to analyze differences in focal gray matter.
Results: The chemotherapy-exposed breast cancer survivors had significantly smaller total 
brain volume (-3.5 ml, p=.019) and gray matter volume (-2.9 ml, p=.003) than the reference 
subjects. No significant differences were observed in white matter volume, hippocampal 
volume, or local gray matter volume.
Discussion: This study shows that adjuvant chemotherapy for breast cancer is associated 
with long-term reductions in total brain volume and overall gray matter volume in the absence of 
focal reductions. The observed smaller gray matter volume in chemotherapy-exposed survivors 
was comparable to the effect of almost 4 years of age on gray matter volume reduction. These 
volume differences might be associated with the slightly worse cognitive performance that we 
observed previously in this group of breast cancer survivors.
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Introduction
Treatment of breast cancer with cytotoxic agents has been associated with structural and 
functional brain changes (Table 1) (1). White-matter pathology has been observed within 
months up to ten years post-treatment. Compared to healthy controls and breast cancer 
patients who never received cytotoxic treatment, chemotherapy-exposed patients had more 
white matter hyperintensities (2, 3) and decreased integrity of major white matter tracts in 
frontal and temporal regions of the brain (4, 5). The integrity of the genu of the corpus callosum 
also was lower in chemotherapy-exposed patients (6). 
Few studies have investigated the association between chemotherapy and gray matter 
volume. One study reported that patients one year post-treatment had smaller local gray 
matter volumes than cancer patients who never received chemotherapy. This was not observed 
in another group of patients who were three years post-treatment (7). A study that strictly 
examined hippocampal volume did not find differences between cancer patients who received 
chemotherapy three years before and those who did not (8). We recently showed that breast 
cancer survivors who completed high-dose chemotherapy almost ten years before had less 
focal gray matter than survivors who never received chemotherapy (4). A prospective study 
observed focal gray matter volume decrease one month after cessation of chemotherapy, 
which recovered in some, but not all regions at one year post-treatment (9).
The four studies described above performed brain volumetrics from one month up to 10 
years post-treatment using different imaging protocols and analytic procedures. Their sample 
sizes were relatively small: the number of chemotherapy-exposed patients ranged from 5-73 
(Table 1) (2-4, 7-10).
To date, it is unclear if standard-dose chemotherapy is associated with long-term effects 
on brain structure. This issue becomes increasingly important as the number of long-term, 
hence elderly cancer survivors is steeply increasing (11) and recent literature shows that 
chemotherapy is associated with cognitive problems in long-term survivors of breast cancer 
(12). Because central nervous system (CNS) regeneration is limited (13), it is possible that 
chemotherapy-induced structural brain changes are persistent rather than transient. 
We evaluated whether breast cancer patients who had been exposed to adjuvant 
chemotherapy on average more than 20 years before, had smaller brain volumes than women 
from the general population without cancer. Hereto we compared 1) brain tissue volumes; 
2) hippocampal volume; and 3) regional gray matter volume of 184 invasive breast cancer 
survivors who had been exposed to chemotherapy and radiotherapy to those of 368 age-
matched healthy control subjects from a population-based study.
Materials & methods
Participants
The current study is embedded in a study investigating the late effects of adjuvant 
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chemotherapy on brain function and structure in elderly breast cancer survivors. It compares 
chemotherapy-exposed invasive breast cancer survivors with female subjects without a history 
of cancer from the Rotterdam Study (RS). Written informed consent was obtained from all 
participants. The institutional review boards of the two participating institutions (the Netherlands 
Cancer Institute/Antoni van Leeuwenhoek Hospital and the Erasmus University Medical Center) 
approved the study.
Chemotherapy-exposed subjects
We selected consecutive female patients with unilateral invasive breast cancer from the 
registries of the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital and the Daniel 
den Hoed Clinic of the Erasmus Medical Center, who had been treated with 6 cycles of CMF 
chemotherapy (Cyclophosphamide 100 mg/m2 on days 1-14; Methotrexate 40 mg/m2 on days 1 
and 8; 5-Fluorouracil 600 mg/m2 on days 1 and 8) between 1976 and 1995. 
We included patients who were between 50 and 80 years of age, in whom invasive breast 
cancer was their first and only malignancy, who had remained disease-free since treatment for 
breast cancer, and who had sufficient command of the Dutch language. Exclusion criteria were 
use of adjuvant endocrine therapy and MRI contra-indications. 
A complete overview of the subject inclusion has been described earlier (14). In short, of 
the 291 patients who were eligible, 195 (67.0%) agreed to participate. Of these 195 women, 
four aborted the scan because of claustrophobia. Three scans were unusable due to motion 
artifacts. Another four were excluded on the basis of cortical infarctions, leaving 184 scans to 
be analyzed.
Decliners were older than subjects who were willing to participate when invitation letters 
were sent ((F
1,289
)=11.13; p<.05).
Healthy reference subjects
Reference subjects were selected from the Rotterdam Study; a population-based prospective 
cohort study that is ongoing since 1990 (15). Among other diseases in the elderly, the study 
targets neurological and psychiatric diseases, and includes an extensive MR brain imaging 
protocol. As of 2008, the study has included 14,926 subjects. To date, 4,898 participants of the 
Rotterdam Study have been invited for the Rotterdam Scan Study (RSS). Exclusion of individuals 
with MRI contraindications (n=389) left 4,509 eligible persons, of whom 4,102 (91%) agreed to 
participate. Due to physical inabilities, imaging could not be completed in 44 individuals. 
Each chemotherapy-exposed breast cancer survivor was matched on age to two randomly 
selected women without a history of cancer of the 4,058 participants of the RSS who completed 
MRI examination. This resulted in a total of 368 reference subjects.
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Methods
MRI Acquisition
Multi-sequence MRI for both cancer survivors and reference subjects was performed on the 
same 1.5-Tesla MRI scanner (General Electric Healthcare, Milwaukee, Wisconsin). During the 
study period, no software or hardware upgrades were performed on the system. Our full scan 
protocol has been described in detail earlier (16).
For this study we used a high-resolution axial MRI sequence, i.e. a T1-weighted 3-dimensional 
fast radiofrequency spoiled gradient recalled acquisition in steady state with an inversion 
recovery prepulse sequence (TR=13.8 ms, TE=2.8 ms, inversion time=400 ms, FOV=25×17.5 
cm2, matrix=416×256 [interpolated to 512×512], flip angle=20°, NEX=1, bandwidth [BW]=12.50 
kHz, 96 slices with a thickness=1.6mm zero-padded in the frequency domain to 0.8 mm, 
interpolated voxel size=0.5×0.5×0.8=0.2 mm3; duration=6 min.).
Remaining scan sequences such as cerebral blood flow and diffusion weighted imaging will 
be described separately.
Acquisition of medical and demographic data
Demographic information and medical data that are associated with brain structure were 
collected for all participants. Sitting blood pressure was measured twice on the right arm with 
a random-zero sphygmomanometer. We used the average of these two measurements (17). 
Data on diabetes, education level, and smoking status were obtained, as they are part of the 
core interview of the Rotterdam Study (15). Depressive symptoms were assessed with the 
Center for Epidemiologic Studies Depression scale (CES-D), which was converted to a sum-
score according to the standard scoring rules. (18) Education level was subdivided into three 
levels: 1) lower vocational education or less; 2) lower secondary education/intermediate 
vocational education/general secondary education; 3) higher vocational education or better. 
Smoking status was subdivided into three levels: current, ever and never smoker. 
Pre-processing and segmentation
Non-uniformity correction and automatic reorientation to the anterior commissure was 
applied to all scans (17). Reorientation was visually inspected and manually corrected if 
necessary. Images were segmented into gray matter, white matter and cerebrospinal fluid 
(CSF) using the ‘new segment’ module in the Statistical Parametric Mapping software version 
8 (SPM8).
Regional gray-matter differences
Regional brain differences were analyzed using voxel-based morphometry (VBM), following 
diffeomorphic anatomical registration through exponentiated lie algebra (DARTEL) under 
SPM8 implemented in Matlab R2010b (MathWorks, Natick, Massachusetts). DARTEL is a 
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fully deformable registration method that is effectively unconstrained by number of degrees of 
freedom. It has proven good segmentation and registration accuracy in comparison with other 
algorithms (19, 20).
First, an initial template was created by averaging all segmentations per tissue class. 
Subsequently, a study-specific template was created on the basis of the individual deformation 
from the initial template of all 184 chemotherapy-exposed survivors and 184 randomly assigned 
age-matched subjects from the total group of 368 reference subjects. This selection was made 
to ascertain equal contributions of both groups to the template. Subsequently, the deformation 
fields of all 552 subjects were warped to the template. Through Jacobian modulation preservation 
of the initial volumes was achieved. The modulated-warped images were smoothed with an 
8-mm full-width at half-maximum Gaussian kernel to increase signal to noise ratio.
Total brain tissue volume
A study-specific brain mask was computed by summing the DARTEL gray matter, white 
matter, and CSF templates and thresholding this image at a probability of 0.5. Tissue volumes 
in milliliters were calculated from masked tissue segmentations in DARTEL space by summing 
all voxels (0.2 mm3 each) of the corresponding tissue class across the whole brain.
Hippocampal volume
Left and right hippocampal volumes were segmented separately using an automated 
segmentation method (21). Briefly, this method was developed in-house and uses both a 
statistical intensity model and a spatial probability map. The intensity model describes the 
typical intensities of the hippocampus and the background. The spatial probability map contains 
for every voxel the probability that it is part of the hippocampus. Both the intensity model and 
spatial probability map were learned from a set of 18 manually labeled hippocampi. Included in 
the region of interest were the dentate gyrus, CA1-4, and the alveus (21).
Analysis
Intracranial volume (ICV) was defined as the sum of gray matter, white matter, and CSF. Total 
brain volume (TBV) was defined as the sum of gray matter and white matter. Analysis of (Co)
variance (AN(C)OVA) and Chi-square tests were used to compare medical and demographic 
characteristics between chemotherapy-exposed and reference subjects. We used general 
linear models to compare groups on gray and white matter volume, CSF, and TBV. 
Whole brain voxel-wise comparison in the context of the general linear model with Family 
Wise Error (FWE) correction was performed in SPM to identify regional gray matter volume 
differences between groups. All primary analyses were adjusted for ICV, height, age, age-
squared, mean systolic and diastolic blood pressure, self-reported prevalence of diabetes, 
education level, smoking status and symptoms of depression, as these have been associated 
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with brain volume (17, 22, 23). To be able to compare the association between chemotherapy 
and brain tissue volume with the effect size of age we additionally ran the same general linear 
model but without including age-square.
Results
Population characteristics are presented in Table 2. Chemotherapy-exposed patients had 
been diagnosed with breast cancer on average 21.1 years before participation in this study at 
a mean age of 42.9 years. They were taller, better educated and had higher diastolic blood 
pressure than women from the reference group. No significant differences were observed 
between the groups regarding age, systolic blood pressure, CES-D score, smoker status, and 
prevalence of diabetes.
Table 2. Population characteristics
Chemotherapy-exposed 
breast cancer survivors 
(n=184)
Reference group (n=368)
mean sd mean sd p
Age in years 64.0 (6.5) 64.0 (6.5) .995
Height in cm 164.9 (6.4) 162.2 (6.0) <.001
Systolic bloodpressure in mm Hg a 140.5 (20.1) 137.7 (20.2) .13
Diastolic bloodpressure in mm Hg a 84.3 (10.5) 80.7 (9.6) <.001
Depression score (CESD) 4.8 (5.7) 5.9 (7.8) .11
Age at cancer diagnosis in years 42.9 (5.4) - - -
Time since chemotherapy in years 21.1 (4.4) - - -
n (%) n (%)
Diabetes 14 (7.6) 16 (4.3) .12
Education level <.001
low b 84 (47.5) 242 (65.8)
intermediate c 41 (22.3) 83 (22.6)
high d 59 (32.1) 43 (11.7)
Smoker status .28
current 22 (12.0) 67 (18.2)
ever 97 (52.7) 180 (48.9)
never 65 (35.3) 121 (32.9)
sd=standard deviation; CESD=Center for Epidemiologic Studies Depression Scale; a =in 
sitting position; b =lower vocational education or less; c =lower secondary education, 
intermediate vocational education and general secondary education; d =higher vocational 
education or better
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Total tissue volumes are presented in Table 3.
Segmentation of the hippocampi failed in seven chemotherapy-exposed patients, leaving 
177 subjects to be analyzed. The chemotherapy-exposed survivors had significantly smaller 
total brain volume (-3.5 ml, p=.019) and smaller gray matter volume (-2.9 ml, p=.003) than the 
reference group. No significant differences were observed in total ICV, white matter volume, 
cerebrospinal fluid volume, or right or left hippocampal volume between chemotherapy-
exposed breast cancer patients and the reference group. In the model without age-square the 
effect of chemotherapy on total brain volume remained -3.5 ml (p=.018) and on gray matter 
volume remained -2.9 ml (p=.003), whereas the effect of age on total brain volume was -0.99 ml 
(p<.001) per year and on gray matter was -0.75 ml (p<.001) per year.
Subsequently, DARTEL revealed no significant regional gray matter volume differences 
between groups. 
Discussion
Here we report the first study on the late effects of standard-dose adjuvant chemotherapy on 
brain volume in a large sample of breast cancer survivors on average more than two decades 
after cessation of treatment. Chemotherapy-exposed breast cancer survivors had significantly 
smaller total brain volume and gray matter volume than reference subjects without a history 
of cancer. No differences were observed in white matter volume, CSF volume, hippocampal 
volume or focal gray matter volume. 
Strengths of our study are the large sample size, the long time since chemotherapy, the 
homogeneous study population regarding cytotoxic agents (regimen, number of cycles), and 
Table 3. Total brain tissue volumes (in milliliter)
Chemotherapy-
exposed breast 
cancer survivors 
(n=184)
Reference group 
(n=368)
Tissue / ROI Mean sd Mean sd β 95% CI for β p
Intracranial Volume 1318.7 136.5 1315.7 185.3 3.0 -13.9 ; 19.8 .73
Brain volume 1087.0 23.5 1090.7 23.9 -3.5 -6.4 ; -0.6 .019
Gray matter 617.0 15.6 620.0 21.1 -2.9 -4.8 ; -1.0 .003
White matter 470.0 17.4 470.6 23.7 -0.6 -2.8 ; 1.6 .59
Cerebrospinal fluid 235.5 15.5 233.8 21.1 1.6 -0.3 ; 3.5 .10
Left hippocampus a 2.9 0.4 2.9 0.6 -0.1 -0.1 ; >0.1 .07
Right hippocampus a 2.9 0.4 2.9 0.6 >-0.1 -0.6 ; 0.4 .81
ROI=Region of Interest; sd=standard deviation; CI=Confidence Interval; a =n chemotherapy-
exposed breast cancer patients=177
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the large population sample of age-matched women without a history of cancer. 
We are aware that our study has some drawbacks that need to be addressed. Because we 
did not include a non-chemotherapy-exposed breast cancer control group we cannot separate 
the effect of chemotherapy and cancer itself. However, the only two studies investigating 
brain structure in breast cancer patients that included both healthy controls and breast cancer 
patients not exposed to chemotherapy did not report a difference between these two groups, 
suggesting no effect of cancer itself on brain structure (7, 9). 
Another point of discussion is whether the findings of this study could also translate to 
breast cancer patients treated with contemporary regimens. Since both cyclophosphamide and 
5-fluorouracil continue to be implemented in current regimens, and these agents, as well as 
many other commonly used agents are independently associated with structural brain changes 
in animals (24, 25), our study results might also apply to contemporary regimens. 
Previously two studies applied voxel-based morphometry to investigate the effects of 
chemotherapy on focal gray matter volume. Inagaki et al. reported smaller right prefrontal and 
parahippocampal gyrus in chemotherapy-exposed patients than non-exposed patients at three 
months post-treatment. However, no volumetric difference was observed between another 
sample of chemotherapy-exposed and non-exposed patients who were more than three years 
post-treatment (7). Likewise, McDonald et al. reported that chemotherapy-exposed patients 
had decreased gray matter in bilateral frontal, temporal and cerebellar regions and in the right 
thalamus at one month post-treatment, but that recovery was seen at one year in several, 
although not all regions (9). These studies suggest that chemotherapy may induce transient 
local gray matter volume reductions that may (partly) recover over time. This is in line with 
the absence of large differences between chemotherapy-exposed survivors and the general 
population more than 20 years post-treatment that we observed. The only other study that 
investigated the association between hippocampal volume and chemotherapy did also not 
observe a relationship between the two (8).
Of all studies that investigated the effect of chemotherapy on brain structure, none 
examined total tissue volumes after cytotoxic treatment (2-4, 7-10). We found significant effects 
of chemotherapy on total brain volume and gray matter volume. In our analysis the lower 
amount of gray matter in chemotherapy-exposed survivors was comparable to the effect of 
almost 4 years of age on gray matter volume. The clinical relevance of this volume difference 
is not straightforward, but considering the effect size, chemotherapy might be associated with 
cognitive problems that we observed previously in this group of patients (26). Two other recent 
studies also reported a negative association between chemotherapy and long-term cognitive 
functioning (12, 27). 
Up till now three studies have reported adverse effects of chemotherapy on white matter as 
measured with diffusion tensor imaging (DTI) (4-6). Therefore it might be that the small effects 
of chemotherapy on total gray matter volume may be accompanied by microstructural white-
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matter changes. 
The exact mechanisms for chemotherapy-associated gray matter volume reductions are 
largely unknown. Postulated explanations are enhanced neural cell death and decreased cell 
division (28), due to crossing of the blood-brain barrier by certain chemotherapeutic agents and 
increased levels of oxidative stress (29). Cell death however is less likely to explain the smaller 
volume, since it is considered irreversible and therefore contradictive to the partial recovery 
of local gray matter reductions that were reported in a longitudinal study after the effects of 
chemotherapy. In addition, another study reported smaller gray matter volumes in a group of 
patients one year post-treatment, but not in a group of patients three years post-treatment (7, 
9).
Conclusion
In this study we investigated the very late effects of chemotherapy on the macrostructure of 
the brain. We observed on average smaller total gray matter volume and total brain volume in 
chemotherapy-exposed breast cancer survivors than in a population-based reference sample 
of age-matched women. This volume difference was comparable to the effect of almost 4 years 
of age on gray matter volume loss. No focal gray matter volume reductions between groups 
were observed. 
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Abstract
Purpose Incidental brain findings defined as previously undetected abnormalities of 
potential clinical relevance that are unexpectedly discovered at brain imaging and are unrelated 
to the purpose of the examination are common in the general population. Because it is 
unclear whether the prevalence of incidental findings in breast cancer patients treated with 
chemotherapy is different to that in the general population, we compared the prevalence in 
breast cancer survivors treated with chemotherapy to that in a population-based sample of 
women without a history of any cancer. 
Patients and methods Structural brain MRI (1.5T) was performed in 191 female CMF 
(Cyclophosphamide, Methotrexate, 5-Fluorouracil) chemotherapy-exposed breast cancer 
survivors. A reference group of 1590 women without a history of cancer was sampled from a 
population-based cohort study. All participants were aged 50 to 80 years. Five trained reviewers 
recorded the brain abnormalities. Two experienced neuro-radiologists reviewed the incidental 
findings.
Results The cancer survivors had completed chemotherapy on average 21 years before. 
Of the 191 subjects, 2.6% had an aneurysm and 3.7% had a meningioma. The prevalence of 
meningiomas and aneurysms was not different between the groups. The prevalence of pituitary 
macro adenomas in the breast cancer survivors (1.6%) was higher than that in the reference 
group (0.1%) (OR=23.7; 95% CI 2.3–245.8).
Conclusion Contrary to commonly held opinions, we did not observe an increased 
prevalence of meningiomas in cancer survivors. Breast cancer survivors previously treated 
with chemotherapy are more likely to develop pituitary adenomas than persons without a 
history of cancer and chemotherapy treatment.
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Introduction
Over the past decade there has been an increase in the number of Magnetic Resonance 
Imaging (MRI) studies investigating chemotherapy associated structural and functional brain 
changes in cancer patients without central nervous system disease (1-9). The focus of these 
studies has been mainly on brain volumes, white matter lesions and integrity of normal 
appearing white matter. An implication of the use of brain imaging is the chance of discovering 
incidental findings, defined as previously undetected abnormalities of potential clinical relevance 
that are unexpectedly discovered and are unrelated to the purpose of the specific outcome 
measures under study (10).
The majority of these incidental findings are asymptomatic and little is known about their 
clinical relevance or prognosis (11). Frequently detected incidental findings in the general 
population are benign primary tumors and aneurysms (11). Whether the prevalence of such 
abnormalities in cancer patients is similar to that in the general population is unclear. None of the 
studies that examined structural or functional brain changes associated with chemotherapeutic 
treatment (1-9) reported on the occurrence of incidental findings. 
We evaluated whether breast cancer patients who have been exposed to chemotherapy 
have an increased prevalence of incidental intracranial findings. We investigated this by 
comparing the prevalence of incidental findings in a large sample of chemotherapy-exposed 
breast cancer survivors with that in a large sample of women who had never been diagnosed 
with cancer from the general population.
Materials & methods
Participants
We used data from a study after the late effects of CMF chemotherapy on brain function 
and structure in older breast cancer survivors. This study compares chemotherapy-exposed 
breast cancer survivors with a population-based sample of women without a history of cancer, 
on several outcome measures and implements including neuropsychological tests and MRI 
of the brain. We selected a reference group from an ongoing population-based cohort study. 
Examination of the breast cancer survivors took place in the research center of this cohort study 
with the same protocol and by the same technicians.
From the registries of the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital 
and the Erasmus University Medical Center-Daniel den Hoed Cancer Center we selected 
consecutive female patients who had been treated between 1976 and 1995 for unilateral invasive 
breast cancer with 6 cycles of CMF (Cyclophosphamide 100 mg/m2 on days 1-14, Methotrexate 
40 mg/m2 on days 1 and 8, 5-Fluorouracil 600 mg/m2 on days 1 and 8) chemotherapy (12). All 
women underwent local radiotherapy. We included women who were between 50 and 80 years 
of age at time of study enrollment, who had sufficient command of the Dutch language, who had 
had invasive breast cancer as their first and only neoplasm, and who were disease-free since 
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primary cancer treatment. Exclusion criteria encompassed use of adjuvant endocrine therapy 
for breast cancer or MRI contra-indications. 
On the basis of information from patient files, 359 women were eligible for participation and 
were hence sent an invitation letter signed by their treating physician. From the 359 patients, 
20 (5.6%) could not be reached, 16 subjects (4.5%) had a health related contra-indication for 
MR imaging, 30 (8.4%) persons were ineligible for MRI assessment due to claustrophobia, and 
2 women (0.6%) had insufficient command of the Dutch language. This left us with 291 eligible 
patients of whom 195 (67.0%) agreed to participate. Four of the 195 participating women 
aborted the scan session because of claustrophobic complaints. The final number of patients 
who completed MRI examination was 191. Written informed consent was obtained from all 
participants. The institutional review boards of the two participating institutions approved the 
study.
A reference group was selected from the Rotterdam Study; a population-based prospective 
cohort study ongoing since 1990 in the Ommoord district, Rotterdam, The Netherlands. (13) 
Of the 4,058 participants of the Rotterdam Study who completed an MRI examination until 
September 2009, we selected all women (n=2206; 54.4%) who were between 50 and 80 years 
of age (n=1881; 85.3%). Next, we excluded all participants with a cancer history based on self-
report and record linkage with general practitioners (n=291; 15.5%), leaving a total reference 
group of 1590 women. 
Methods
Brain MRI acquisition
All scans were obtained at the Rotterdam Study research center in Rotterdam, the 
Netherlands, using a 1.5-T scanner with an eight-channel head coil (GE Healthcare). Two trained 
technicians performed all examinations in a standardized way. The MRI protocol was identical 
for all participants has been described previously by Vernooij et al. (11).
Assessment of incidental findings
All scans were read for incidental findings of potential clinical relevance by one of five trained 
reviewers. Examples include brain tumors, aneurysms, subdural fluid collections, and arachnoid 
cysts. Reviewers were blinded for information on the subjects. Brain findings that were not 
considered clinically relevant and were not recorded as incidental findings included simple 
sinus disease and variations from the norm, such as pineal cysts, ventricular asymmetry, and 
enlarged Virchow–Robin spaces (11). Diagnoses were not confirmed by histologic studies but 
were made on the basis of MRI findings characteristic of each lesion. Case definitions for each 
incidental MRI finding have been described previously by Vernooij et al. (11). Two experienced 
neuro-radiologists reviewed and reached a consensus on all initially reported abnormalities 
(11). The management of incidental findings followed the protocol of the Rotterdam Study and 
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was defined before the start of the study. Depending on the detected abnormality and after 
consultation with involved clinicians, persons with incidental findings requiring additional clinical 
workup or medical treatment were informed and referred to a relevant medical specialist.
Statistical analysis
Prevalence of incidental brain finding were compared between the chemotherapy-exposed 
women and the women from the reference group using age-adjusted binary logistic regression 
analysis. We subsequently examined the effect of type of menopause and age at menopause 
on the risk to develop incidental findings. In addition, within the breast cancer survivors we 
investigated whether radiotherapy field was associated with the development of incidental 
findings. Alpha levels were set at p=0.05 for all analyses.
Results
Eligible breast cancer patients who declined participation were older than subjects who were 
willing to participate at the time invitation letters were sent (F
1, 289
=11.13, p<.05).
Table 1 presents the characteristics of the breast cancer survivors and the reference group. 
Chemotherapy-exposed subjects were older than women from the reference group (F=59.6; 
p=<.001). The mean age at breast cancer diagnosis was 42.9 years and time since treatment 
was on average 21.2 years. Of the 191 chemotherapy-exposed participants 161 (85.3%) became 
menopausal following breast cancer treatment at a mean age of 43.0 years. For the whole 
sample, breast cancer patients menopause occurred on average at age 43.8 years (sd=6.1), 
which is significantly earlier than for women from the reference group who reached menopause 
at a mean age of 48.6 years (sd=6.0) (F=105.0; p=<.001). Of the 191 breast cancer survivors, 
85.3% received parasternal radiotherapy, 9.4% received radiotherapy at the breast or chest 
wall, 3.7% underwent radiotherapy according to the McWhirter protocol and for three patients 
(1.6%) radiotherapy field was unknown.
Table 2 presents the prevalence of age-adjusted incidental findings. Of the breast cancer 
survivors 2.6% had an aneurysm, 3.7% had a meningioma and 1.6% had a pituitary macro-
adenoma. There were no significant differences in the prevalence of meningiomas and 
aneurysms between women who underwent chemotherapy and the reference group. However, 
chemotherapy-exposed patients had a higher prevalence of pituitary macro adenoma than the 
reference group (OR= 23.7; 95% CI= 2.3-245.8). Besides aneurysms, pituitary adenomas and 
meningiomas in this sample of merely 200 women we did not find any other findings such 
as gangliomas, vestibular schwannomas or subdural hematomas. We found no association 
between age and type of menopause (chemotherapy induced versus natural) with any of the 
incidental findings. In the chemotherapy-exposed patients, radiotherapy field was not associated 
with the prevalence of any of the incidental findings.
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Discussion
We found no difference in the prevalence of asymptomatic meningiomas and aneurysms 
identified on MRI scans in 50 to 80-year-old former breast cancer patients who had been treated 
with chemotherapy, on average 21 years before, and a population-based sample of women of 
the same age without a history of cancer. However, the former breast cancer patients had a 
higher prevalence of asymptomatic pituitary macro adenomas than the reference group. 
Up till now, a non-significant positive association between pituitary adenomas and benign 
breast tumors has been reported (14, 15). To our knowledge, no previous data are available 
Table 1. Characteristics of the breast cancer survivors and the reference group
Breast cancer 
survivors (N=191)
Reference group 
(N=1590) p
Number of participants 191 1590
Mean age in years (sd) 64.1 (6.4) 60.2 (6.6) <.001
Mean age at menopause: total (sd) 43.8 (6.1) 48.6 (6.0) <.001
sponteaneous menopause in years (sd) 47.5 (4.3) 50.2 (4.3) <.001
induced menopause in years (sd) 43.0 (7.2) 45.7 (7.1) .002
Mean age of cancer diagnosis in years (sd) 42.9 (5.3)
Mean time since treatment in years (sd) 21.2 (4.4)
Radiotherapy field:
parasternal (%) 163 (85.3)
breast / chest wall (%) 18 (9.4)
McWhirter (%) 7 (3.7)
unknown (%) 3 (1.6)
sd= standard deviation
Table 2. Prevalence of age-adjusted incidental findings
Reference group 
(N=1590)
Breast cancer 
survivors (N=191)
n (%) n (%) OR 95% CI
Aneurysm 37 (2.3) 5 (2.6) 1.1 0.42 – 2.91
Meningioma 36 (2.3) 7 (3.7) 1.4 0.62 – 3.33
Pituitary macro adenoma 1 (0.1) 3 (1.6) 23.7 2.28 – 245.76
OR= odds ratio; CI= confidence interval
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on a relationship between pituitary adenomas and invasive breast cancer. Therefore it remains 
undermined whether the excess number of pituitary adenomas in the current group of invasive 
breast cancer survivors could be explained by their first primary neoplasm.
A possible explanation for the elevated prevalence might be the relation of pituitary 
adenomas and postmenopausal status. In a case-cohort study Schoemaker et al. reported a 
3-fold risk increase in postmenopausal women, which was even greater for surgically induced 
menopause compared to natural menopause (OR 6.7), and was greatest in women who entered 
menopause before the age of 40 years (OR 7.5) (15). 
It is known that CMF may induce menopause in a substantial number of patients. A study 
by Goodwin et al. showed that use of CMF increased the risk of onset of menopause within 1 
year after breast cancer diagnosis in 40-year-old women from less than 5% to more than 40%. 
In 50-year-old women, this risk was increased from approximately 20% to close to 100% (16). 
In our sample of cancer patients 85.3% became menopausal directly after treatment at a mean 
age of 43.0 years. The relative early and young mean age at menopause may have put these 
women at a higher risk for pituitary adenomas. However, type of menopause and menopausal 
age of onset were no predictors for the risk of incidental findings in our models, although this 
could also be due to the small number of incidental findings.
Several studies have reported an elevated risk of developing a meningioma after breast 
cancer and vice versa, with standardized incidence rates ranging from 1.57 to 1.90 (17-
22). Proposed explanations for the co-occurrence of these tumors include a) the hormonal 
dependency of both tumors as estrogen and progesterone receptor expression are frequently 
present in breast carcinomas as well as in meningiomas, and the observation that meningiomas 
tend to grow rapidly during pregnancy (23-25), b) the fact that both tumors have a higher 
incidence in females (20), and c) intake of unsaturated fat as a risk factor for both malignancies 
(20).
In contrast with the literature, we did not find a higher prevalence of meningiomas in 
former breast cancer patients compared to the general population. Potential explanations 
for the divergent observations are the different study designs and populations. The incidental 
findings in our studies concerned asymptomatic meningiomas whereas other studies focused 
on symptomatic meningiomas. Moreover, previous studies used data from regional (22) and 
national (17-20) cancer registries that include almost all consecutive breast cancer patients 
in a particular time frame whereas we selected a more homogeneous group of breast cancer 
patients who were all treated with adjuvant chemotherapy and who never developed recurrent 
breast cancer nor a second malignancy.
Some epidemiologic studies showed that increased estrogen levels are associated with a 
higher risk for breast cancer in pre- and postmenopausal women (26-29). Because estradiol 
also might stimulate growth of meningiomas (30) one might expect a higher prevalence of these 
neoplasms in breast cancer patients. However, the fact that our breast cancer survivors went 
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through menopause much earlier than women from the general population may have decreased 
the prevalence of meningiomas in our study group as a result of a significant period of lower 
estrogen levels. Furthermore, Wigertz et al. postulated that sex hormones influence tumor 
growth rather than tumor initiation (31). These arguments may explain why we did not find a 
difference in the prevalence of asymptomatic meningiomas between breast cancer survivors 
and the general population and also the discrepancy of the prevalence of menigiomas that we 
observed in the breast cancer survivors and the prevalences of symptomatic meningiomas in 
the published studies.
No difference in the prevalence of aneurysms was observed between chemotherapy-
exposed breast cancer survivors and the reference group. In-vitro studies have showed that 
chemotherapy might induce endothelial cell damage (32, 33), which in rats has been related 
to cerebral aneurysm formation (34). Data in humans hereon are lacking. Radiotherapy to the 
head, neck and brain has been associated with intracranial aneurysms (35). To our knowledge, 
no studies have investigated if ionizing radiation scatter from radiotherapy for breast cancer, 
for example at the supraclavicular field, is also associated with the formation of intracranial 
aneurysms. Our results however indicate no association between breast cancer and CMF 
chemotherapy or radiotherapy-field and the development of intracranial aneurysms.
We are aware that our study has some drawbacks. As a result of the inclusion criteria that 
we applied, our population under study is a selection, since we have only included breast cancer 
patients who underwent cytotoxic treatment, who did not develop breast cancer recurrence 
and who were never diagnosed with a second primary cancer. This limits the generalizability 
of the study results, because breast cancer patients who have developed a second malignancy 
may be at higher risk to subsequently develop intracranial neoplasms than those who have not 
(36).
Moreover, we cannot separate the effect of chemotherapy and breast cancer itself on the 
risk of developing intracranial neoplasms or aneurysms. Finally, although our sample of former 
breast cancer patients was large enough to investigate the more common incidental findings, 
the number of subjects was too small to investigate less common incidental e.g. gangliomas.
Another point of discussion is whether the findings of this study apply to breast cancer 
patients treated with contemporary regimens, since it is unclear whether the current 
observation on the associations between adjuvant chemotherapy for breast cancer and the 
development of incidental findings is exclusively linked to the CMF regimen. If cancer rather 
than its treatment is a risk factor for incidental findings, risk differences between the CMF 
regimen and contemporary regimens may not exist. If differences in hormone levels are in the 
causal pathway of incidental findings, the risk may be different for contemporary regimens, as 
the occurrence of premature treatment- induced menopause varies by regimen. (37) When 
development of incidental findings is caused by cytotoxic treatment itself, similar risks may be 
expected for contemporary regimens compared to the CMF regimen; both cyclophosphamide 
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and 5-fluorouracil are frequently implemented in current regimens and these agents as well 
as many other commonly applied agents are independently associated with structural brain 
changes (38, 39) and comprised vessel integrity in animals (40, 41). 
A major strength of this study is the large reference group from which we obtained a 
precise estimate of the prevalence of incidental findings in women from the general non-cancer 
population. Up till now, no other study has looked at the relation between breast cancer or 
adjuvant chemotherapeutic treatment and asymptomatic intracranial neoplasms or aneurysms. 
The long time since treatment enabled us to look at neoplasms and aneurysms that normally 
take a long time to develop and of which the initiation or progression may have been triggered 
by the cytotoxic treatment. 
Clinical implications
The number of studies implementing MRI in the field of cancer and cognition is rapidly 
increasing and as a result the number of incidental findings will progress similarly. No strict 
guidelines on the management of incidental findings are available and investigators vary greatly 
in the way they handle them (11, 42). For the interpretation of the prevalence of incidental 
findings data from an appropriate reference population is of crucial importance. Up till now 3 
studies have presented date on the prevalence of incidental findings in healthy adults (43-45), 
and only one study has described prevalences of incidental findings in the general population 
(11). This is the first study that presents the prevalence of incidental findings in breast cancer 
survivors who have been treated with chemotherapy. The observation of an increased incidence 
of pituitary macro adenomas, possibly in relation to an early postmenopausal status needs 
confirmation as with the current treatment strategies the number of long-term breast cancer 
survivors is increasing.
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Adjuvant chemotherapy is widely used in the treatment of breast cancer (1). Adverse effects that 
have been ascribed to the cytotoxic treatment include cognitive dysfunction and brain structural 
alterations, which have been observed shortly up till several years post treatment (2-7). Not much 
is known about the long-term consequences of adjuvant cytotoxic treatment on the brain. However, 
as the number of long-term survivors is increasing (8-11) this topic is gaining more interest (12).
In this thesis I investigated the late effects of adjuvant CMF (Cyclophosphamide, Methotrexate, 
5-Fluorouracil) chemotherapy, given for breast cancer, on brain function and structure. In this 
chapter I will summarize and interpret the main findings of the studies that have been conducted 
in the framework of this thesis. Subsequently I will get back to the research question that was 
formulated in Chapter 1: “Is adjuvant CMF chemotherapy given for early stage breast cancer 
associated with long-term impaired cognitive functioning and brain structure?”. Furthermore, I will 
discuss methodological considerations that limit the interpretation of the studies, and consider the 
clinical implications that result from these studies. Finally, I’ll make suggestions for future research 
following this thesis. 
Breast cancer patients that participated in the studies on which this thesis is based had been 
treated with CMF chemotherapy, on average more than 20 years before, in the Netherlands Cancer 
Institute/Antoni van Leeuwenhoek Hospital or the Daniel den Hoed Cancer Center of the Erasmus 
MC University Medical Center. Reference subjects were sampled from the Rotterdam Study (13); 
an ongoing population-based cohort study. By sampling reference data from the Rotterdam Study I 
was able to compare the test results of the chemotherapy-exposed breast cancer survivors to those 
of the general population. Because of the extensive set of cognitive, psychological, cardiovascular 
and neuro-imaging measures that are collected in the framework of the Rotterdam Study it was 
possible to investigate the impact of CMF chemotherapy on these various interdependent outcome 
measures with subsequent correction for several confounding factors. In addition, it enabled me to 
focus all our efforts and resources on including as much breast cancer survivors as possible. The 
eventual inclusion of large numbers of subjects allowed me to adjust for multiple confounders.
Summary and interpretation of main findings
Previous studies
When I started this study, little was known about the potential late effects of adjuvant 
chemotherapy on cognitive functioning. In Chapter 2 I reviewed the literature on the long-term 
outcomes of adjuvant chemotherapy given for non-central nervous system cancer, on cognitive 
functioning, brain structural and functional alterations, and the risk of dementia. Studies were 
selected if the cancer patients under investigation were at least five years post-treatment. Six studies, 
including our own, were identified that assessed patients with neuropsychological tests five or more 
years after cessation of adjuvant cytotoxic treatment. These studies showed that chemotherapy 
is associated with long-term subtle cognitive dysfunction in some, but not all patients. The effects 
were mainly observed in the domains of verbal memory and executive functioning. Three neuro-
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imaging studies in patients that were five or more years post-treatment were identified. Results 
from these studies are in line with the previously described late cognitive effects studies and 
show that cytotoxic treatment is associated with less long-term gray matter volume, worse global 
and focal white matter integrity, and hypo-activation of brain areas during cognitive tasks. Four 
studies on the risk of dementia following chemotherapy showed no increased risk for dementia 
following cytotoxic treatment, yet had severe methodological limitations and cannot be considered 
as conclusive. The results from this review suggest that five or more years after cessation of 
treatment, various regimens of adjuvant chemotherapy are associated with impaired cognitive 
functioning possibly as a result of chemotherapy-induced structural brain changes. The majority 
of the reviewed neuropsychological studies had small sample sizes and investigated the effects of 
adjuvant chemotherapy in patients who completed cytotoxic treatment on average less than ten 
years before. Reliable estimates of the very late effects of adjuvant chemotherapy are therefore 
largely unknown. 
Cognitive functioning
To investigate if conventional-dose adjuvant chemotherapy is associated with long-term cognitive 
functioning I compared neuropsychological test outcomes of 196 breast cancer patients treated 
with the adjuvant CMF regimen on average more than 20 years previously (range ~14-30 years) 
to the neuropsychological test outcomes of more than 1500 women from the general population 
without a history of cancer. CMF chemotherapy has been the main choice of adjuvant treatment for 
breast cancer up till the early nineteen nineties. It is therefore currently the only regimen of which 
the late cognitive adverse effects can be investigated in sufficiently large numbers (14). In Chapter 
3 I reported the results of this study, which showed that chemotherapy-exposed breast cancer 
survivors performed worse on several neuropsychological tests than population based reference 
subjects without a history of cancer. Significant differences were observed between groups on 
cognitive tests of immediate and delayed verbal memory, processing speed, executive functioning 
and psycho-motor speed. Also on a summary measure of the neuropsychological test results that 
allowed for mutual correlation, the ‘Mahalanobis Distance’ (15-18), the reference group significantly 
outperformed the breast cancer survivors. Mean scores on a dementia screener (i.e. the Mini 
Mental State Examination (MMSE)), did not differ between groups. Besides having worse cognitive 
functioning, the chemotherapy-exposed survivors also reported more often memory complaints. 
Similar to studies conducted shortly after cessation of cytotoxic treatment, no significant correlation 
was found between objective cognitive functioning measured with the neuropsychological tests 
and self reported memory complaints (19). Memory complaints were associated with symptoms of 
depression; an association that has been observed previously in chemotherapy-exposed survivors 
(19), and various other patient populations (20, 21).
The mechanisms by which chemotherapy may induce cognitive dysfunction are currently under 
intensive investigation. Studies so far have shown that many common chemotherapeutic agents 
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directly affect central nervous system cells (22). For long, it has been thought that chemotherapy 
cannot enter the brain, because of the blood-brain barrier that restricts the diffusion of toxins into 
the brain parenchyma (23). However, under several conditions specific types of drugs are able to 
cross the blood-brain barrier (24, 25). Both methotrexate and 5-fluorouracil have proven to be able 
to cross the blood brain barrier in low doses (26, 27). Because neuronal regeneration is limited 
(28), the effects of chemotherapy on brain structure that have been found shortly after cessation of 
treatment might be long-lasting (2, 3, 5, 6, 29, 30). 
Brain structure
To investigate if adjuvant chemotherapy is associated with long-term brain structure I compared 
almost two hundred breast cancer survivors who had been treated with CMF chemotherapy, on 
average more than 20 years before, to an age-matched reference group that I sampled from the 
Rotterdam Scan Study (31). The two groups were compared on several state of the art neuro-
imaging outcome measures, including total brain volume, total gray and white matter volume, focal 
gray matter volume, and global and focal white matter microstructural integrity. I used two different 
techniques to assess focal gray matter volume; a widely used hypothesis free technique known as 
‘Voxel Based Morphometry’ (32) and an in-house developed automated region of interest (ROI) 
analysis in which I specifically looked at hippocampal volume (33). The effect of chemotherapy 
on Hippocampal volume is of particular interest as animal studies showed a detrimental effect 
of cytostatic agents on hippocampal structure and learning (34). Moreover, together with the 
prefrontal cortex, this brain structure is of major importance for consolidation of episodic and 
semantic memory (35, 36) and several neuropsychological studies, including the one discussed 
in Chapter 3, showed a negative relationship between cytotoxic treatment and memory function 
(7, 37). In Chapter 4.1 I discussed the outcomes of my volumetric imaging study. The results of 
these analyses showed that CMF chemotherapy-exposed breast cancer survivors had less total 
brain volume and less gray-mater volume than the population based reference subjects. These 
results did not change after subsequent adjustment for potential confounders such as age, height, 
cardiovascular risk factors, symptoms of depression, and education level. 
Apart from the potential late effects of adjuvant CMF chemotherapy on the macrostructure of 
the brain I was also interested in the effect of chemotherapy on the integrity of the microstructure 
of the white matter, as damage to the latter has been associated with cognitive dysfunction (38). 
Microstructural white matter integrity can be characterized using diffusion tensor imaging (DTI). DTI 
visualizes the extent and directionality of the diffusion of water molecules within brain tissue at the 
voxel level. Generally, water diffusion in white matter fiber bundles is anisotropic as it is hindered by 
tissue architecture (axonal membranes and myelin) and therefore more prominent along the fiber 
direction. Although the biological background is complex, increased diffusivity is often interpreted 
as being related to myelin damage, demyelination or axonal injury (39-41). I used tract based spatial 
statistics (TBSS) (42) to analyze the long-term differences in focal and global white matter integrity 
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between the previously described sample of adjuvant CMF chemotherapy-exposed breast cancer 
survivors treated on average more than 20 years before (range ~14-30 years), and an age-matched 
reference group derived from the Rotterdam Scan Study (31). In Chapter 4.2 the results of this 
study are discussed. No differences were observed in global or focal microstructural white matter 
integrity between groups. However, within the group of chemotherapy-exposed breast cancer 
survivors microstructural white matter integrity was significantly worse with longer times since 
treatment. A possible explanation for these results is that the group of chemotherapy-exposed 
cancer survivors was healthier at baseline than the reference group. This idea is supported by the 
fact that the breast cancer patients were taller, smoked less, had lower BMI, had less symptoms of 
depression, and were better educated than the reference subjects. This may have resulted partially 
from the fact that cancer survivors are prone to adopt a healthier lifestyle after the cancer diagnosis 
(43, 44). Because education level, BMI, and smoking habits all have been associated with white 
matter integrity (45-47), it is possible that at baseline the chemotherapy-exposed survivors had 
better white matter integrity than the reference subjects. 
As stated, our understanding of the potential mechanisms underlying chemotherapy-induced 
brain structural changes is still limited. We considered that the difference in total cerebral gray 
matter volume that I observed between chemotherapy-exposed breast cancer survivors and 
reference subjects (see Chapter 4.1) might be related to chemotherapy-induced differences in 
cerebral perfusion. Reductions in total cerebral blood flow (tCBF) have been associated with cortical 
gray matter atrophy (48). In addition, adjuvant chemotherapy has been linked to endothelial damage 
and intima-media thickness of the common carotid artery (49, 50). Because degree of carotid 
stenosis and size of carotid artery plaques have been related to cerebral blood flow (51), one could 
hypothesize that chemotherapy-exposed patients have reduced tCBF as a result of worse carotid 
artery integrity. To investigate if adjuvant chemotherapy is associated with carotid artery plaques 
and with cerebral perfusion and blood flow, I compared the prevalence of plaques scores and tCBF 
and perfusion between 187 breast cancer survivors treated with adjuvant CMF chemotherapy on 
average more than 20 years before, and a twice as large age-matched population-based sample of 
women without a history of any cancer. The presence of carotid artery plaque scores was measured 
with ultrasound and tCBF was measured with non-invasive 2D phase contrast MRI. Because tCBF 
is strongly related to brain volume (52), I subsequently calculated cerebral perfusion by dividing 
tCBF by brain volume. In Chapter 4.3 I presented the outcomes of these analyses. No differences 
were observed between the groups on any of the outcome measures, indicating that chemotherapy 
is neither associated with long-term carotid artery integrity, nor with cerebral perfusion or total 
cerebral blood flow, and as such can not explain the differences in gray matter volume and white 
matter microstructural integrity between groups that I observed. 
Incidental findings
An implication of the use of neuro-imaging is the chance of discovering incidental findings, 
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defined as previously undetected abnormalities of potential clinical relevance that are unexpectedly 
discovered and are unrelated to the purpose of the specific outcome measures under study 
(53). The majority of incidental findings are asymptomatic and little is known about their clinical 
relevance or prognosis (54). Frequently detected incidental findings in the general population are 
benign primary tumors and aneurysms (54). Whether the prevalence of such abnormalities in 
cancer patients is similar to that in the general population is unclear. None of the neuro-imaging 
studies on the association between chemotherapy and brain structural alterations reported on the 
occurrence of incidental findings (2, 3, 5, 6, 29, 30, 55-60). To study if the prevalence of intracranial 
incidental findings in chemotherapy-exposed breast cancer patients is similar to that of the general 
population I compared the prevalence of incidental findings in 191 CMF chemotherapy-exposed 
breast cancer survivors, treated on average more than 20 years ago and aged 50 to 80 years, 
to that of 1590 cancer-free subjects within the same age range sampled from the population-
based Rotterdam Scan Study (31). All incidental findings were recorded by experienced medical 
doctors and reviewed by two neuro-radiologists. In Chapter 5 I present the results of the group 
comparisons. Within the chemotherapy-exposed breast cancer survivors I observed three different 
types of intracranial incidental findings; aneurysms, meningiomas, and pituitary macro adenomas. 
I observed a higher age-adjusted prevalence of pituitary macro adenomas in the breast cancer 
survivors than in the population-based sample. No significant differences were observed between 
groups regarding aneurysms, or, contrary to commonly held opinions (61-66), the prevalence of 
meningiomas. These study results warrants further investigation of the prevalence of incidental 
findings in chemotherapy-exposed cancer patients and emphasizes the need for strict protocols on 
the assessment and follow-up of incidental findings. 
Answer to my research question and general conclusion
Adjuvant CMF chemotherapy given for breast cancer is associated with long-term worse 
cognitive functioning, less total gray matter volume, and worse white matter microstructural 
integrity, but not with total cerebral blood flow, cerebral perfusion, or plaques in the carotid artery. 
By comparing chemotherapy-exposed breast cancer survivors to a reference population without 
a history of cancer it is not possible to distinguish the effects of chemotherapy and cancer itself. 
My findings suggest that chemotherapy-induced gray matter volume reductions and worse white 
matter microstructural integrity may be part of the mechanisms underlying the observed long-term 
cognitive dysfunction. This is in line with previous studies in the general population that showed 
that both worse microstructural white matter integrity (38), and smaller cerebral gray matter 
volume (67) are associated with cognitive dysfunction. I did not observe differences in cerebral 
perfusion between the chemotherapy-exposed survivors and the reference group and therefore 
it is unlikely that chemotherapy-induced altered cerebral perfusion is causing the observed brain 
structural differences nor is it responsible for the differences in cognitive functioning or brain 
structure between the groups. Previous studies that simultaneously investigated brain functioning 
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using neuropsychological tests and structural and (2, 5, 6, 55) functional MRI (56, 58, 68), positron 
emission tomography (PET) (69), or electro-encephalography (EEG) (70, 71), support the idea that 
cerebral alterations in chemotherapy-exposed breast cancer patients are associated with cognitive 
dysfunction. 
I observed global but not focal effects of adjuvant CMF chemotherapy on gray matter volume 
and white matter integrity. Other studies on the effects of cytotoxic treatment on brain structure 
observed focal effects of chemotherapy on brain volume (6, 55), brain function (56, 58), and white 
matter integrity (2, 5, 55), but never reported on the presence or absence of global effects of 
cytotoxic treatment. It may be that the combined focal effects of chemotherapy underlie a global 
effect in brain structure. The fact that neuro-imaging studies shortly after cessation of treatment 
found chemotherapy-induced focal differences in brain structure that at least partially recover 
at longer times since treatment (6, 30, 59), suggests that at very long times after completion of 
treatment no focal effects of chemotherapy may be observed. 
The fact that I did not observe differences in the mean score on a dementia screener between the 
chemotherapy-exposed breast cancer survivors and the reference subjects suggests that although 
the breast cancer survivors have more cognitive problems that are associated with chemotherapy 
and/or the disease, it does not lead to an accelerated incidence or increased risk of dementia, at 
least not within the age range covered in this study.
Chemotherapy-induced menopause
Early menopause may be an intermediate factor in the effect of adjuvant CMF chemotherapy 
on brain function (22). Adjuvant CMF is known for its ability to induce menopause. Goodwin et 
al. showed that within 1 year after breast cancer diagnosis, in 40-year-old women who had been 
treated with CMF, the onset of menopause increased from less than 5% to more than 40%. In 
50-year-old women, this risk was increased from approximately 20% to close to 100% (72). In our 
sample of cancer patients 85.3% became menopausal directly after treatment at a mean age of 
43.0 years (see Chapter 5). Some studies have reported effects of surgically and chemically induced 
menopause on cognitive functioning, in particular on verbal and working memory, although several 
others did not report such a relationship (73, 74). Nevertheless, within my study population I found 
no differences in cognitive functioning between women who reached menopause before or after 
the age of 45, and no correlation between time since menopause and white matter microstructural 
integrity. 
Methodological considerations
Here I will discuss the methodological considerations that generally apply to the studies in this 
thesis. Methodological considerations that concern individual studies have been discussed in the 
respective chapters. 
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Study design
The studies presented in this thesis are the first that assessed the very late effects of conventional-
dose adjuvant chemotherapy on brain structure and function in large numbers of patients. The 
patients under investigation in this study had all been treated more than 13 years up to 30 years 
prior to participation. A prospective cohort study would be the most optimal design to answer 
my research question. However, the long follow-up of large numbers of breast cancer patients, 
taken into account the dropout of subjects, would be a cost-inefficient endeavor, which is why the 
current cross-sectional design was initially selected. The downside of this design is that I could not 
investigate any changes in cognitive performance and brain structure that result from cytotoxic 
treatment. Even though the large samples of breast cancer survivors and reference subjects from 
the general population enabled precise estimates, I do not know if these women were comparable 
at baseline (i.e. at the time of the breast cancer diagnosis). My data suggest that the group of 
chemotherapy-exposed survivors and the reference subjects were not fully comparable at baseline. 
For example, the chemotherapy-exposed breast cancer patients on average completed higher 
levels of education than the reference subjects. Education level has been associated with cognitive 
functioning (75), and brain structure (46, 76) and therefore, at baseline, cognitive function and brain 
structure may have been better in breast cancer survivors than reference subjects. In addition, 
breast cancer patients are prone to adopt a healthier lifestyle after the cancer diagnosis (43, 44), 
which has been associated with better brain function, structure and metabolism (45, 47, 77). Hence, 
the negative effect of CMF chemotherapy may have been underestimated.
Selection of chemotherapy-exposed breast cancer survivors
To be able to investigate the long-term adverse effects of chemotherapy in sufficiently large 
numbers, I included women who had been treated with CMF chemotherapy, as this was the 
regimen of choice from the mid nineteen seventies up until the mid nineteen nineties (14). On 
average these women had been diagnosed with breast cancer 21 years before entering the 
study. It is not impossible that selection bias within the group of eligible breast cancer survivors 
could have led to an underestimation of the effect of chemotherapy. Generally, healthy subjects 
are more prone to participate in scientific studies than their less healthy counterparts (78). This 
type of selection bias is often referred to as the healthy worker effect. Of the 292 subjects that 
were eligible to participate in the studies described in this thesis, 96 declined participation. These 
women were older than women that participated. To investigate if there was a possible selection 
bias I invited the 96 women that declined participation and all women who could not complete MRI 
assessment because of claustrophobia, but who were otherwise eligible for the main study (n=30), 
for an at-home testing session. Of these 126 women, two had passed away and two could not be 
contacted. Of the 122 eligible participants 48 women (38%) agreed to participate. They subsequently 
underwent the same neuropsychological assessment and interview as used in the main study, at 
their own home. Home-participants had worse processing speed compared to center-participants, 
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although after adjustment for multiple comparisons there were no differences between groups, 
suggesting no selection bias regarding cognitive functioning. Furthermore, after adjustment for 
multiple testing, center participants did not differ from home participants on socio-demographic 
variables, cardiovascular risk factors or neurologic diseases. Although I cannot completely rule out 
selection bias, as not all decliners participated in the at-home testing session, and because I did not 
have information on brain structure of the declining breast cancer survivors, I found no suggestion 
for selection bias regarding cognitive functioning.
Reference population 
To date, the Rotterdam Study has included almost 15,000 subjects from the Ommoord area over 
three cohorts (13, 31). The first cohort (RS-I) that was recruited from 1990 onwards comprises of 
7,893 subjects 55 years of age and older, of whom 203 underwent brain imaging in the framework 
of the Rotterdam Scan Study (RSS). In 2000 the second cohort (RS-II) was recruited that comprises 
of 3,011 subjects who had become 55 years of age or came to live into Ommoord. Of RS-II, 895 
subjects completed MRI examination. Finally, in 2006, the third cohort (RS-III) of 3,932 subjects 
aged 45 years to 54 years was recruited. Of these subjects 2,947 completed brain imaging. As the 
majority (71%) of the scans was obtained from subjects from RS-III who were between 45 and 54 
years of age, the distribution of eligible reference subjects for the MRI studies was skewed to the 
left (see Figure 1). Because of the relatively low number of subjects in the higher age categories 
I was not able to match on education level as adequately as I was able to match on age. As a 
result, the distributions of highest attained education level between chemotherapy-exposed cancer 
survivors and reference subjects differed significantly. Although I adjusted for age, I cannot rule out 
the possible residual effect of education on brain structure (46, 76).
Clinical implications 
The goal of my study was to explore the potential long-term effects of standard dose adjuvant 
CMF chemotherapy given for breast cancer on brain function and structure.
The finding that chemotherapy-exposed breast cancer survivors who were on average more 
than 20 years post-treatment performed worse than reference subjects on neuropsychological tests 
measuring verbal memory, information processing speed, executive functioning, and psycho-motor 
speed has several important implications. First of all, it indicates that chemotherapy for breast cancer 
is associated with long-term cognitive dysfunction. Whether this effect is due to chemotherapy, 
breast cancer itself or both is not entirely clear. Nevertheless, since even mild cognitive dysfunction 
is associated with lower quality of life (79), this outcome is important considering the large and still 
increasing number of breast cancer survivors (8-11). Although the current findings might not justify 
informing patients about the potential late effects of chemotherapy at the moment they have to 
decide whether or not to undergo chemotherapy, they should stimulate clinicians to be perceptive 
of cognitive problems in patients with a history of adjuvant CMF chemotherapy for breast cancer. 
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From a patient perspective the results presented in this thesis call for the availability of information 
for patients on the potential long-term effects of chemotherapy on cognitive functioning. Because 
this is the first study on the very late effects of chemotherapy on cognitive functioning, replication 
of our results is necessary before it is justified to inform patients about long-term cognitive 
consequences of adjuvant cytotoxic treatment. Until then, information on the long-term effects 
of adjuvant cytotoxic treatment on cognitive functioning may be added to the currently available 
patient-information leaflet on the adverse-cognitive effects of chemotherapy. Cognitive dysfunction 
should be considered as a potentially serious adverse effect of chemotherapy and therefore trials 
investigating new cytotoxic regimens should include standard evaluation of cognitive functioning.
Cytotoxic regimen under investigation
I investigated the long-term adverse effects the CMF regimen. Nowadays, CMF chemotherapy 
is not the main choice of adjuvant therapy for invasive breast cancer anymore (80). Whether 
contemporary regimens are also associated with long-term brain structural and functional 
alterations, and whether these effects are similar the late effects of adjuvant CMF chemotherapy I 
observed is largely unknown. Nevertheless, as described in Chapter 2, neuropsychological (81-84), 
and neuro-imaging (6, 55, 58, 60) studies investigating the effects of currently prescribed regimens 
show that shortly up till several years after cessation of treatment these contemporary regimens 
Figure 1. Number of subjects per age class for the chemotherapy-exposed breast cancer 
survivors and reference subjects. Gray bars indicate the number of chemotherapy-exposed 
breast cancer survivors; Black bars indicate the number of reference subjects available from 
the Rotterdam Scan Study
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adversely affect brain function and structure. My studies may act as a model to investigate the 
potential long-term effects of contemporary regimens on cognitive function and brain structure. 
In addition, the cytotoxic agents cyclophosphamide and 5-fluorouracil that are part of the CMF 
regimen are still frequently incorporated in conventional contemporary regimens, such as TAC 
(taxotere, adriamycine, cyclophosphamide) or FEC (cyclophosphamide, epirubicin, fluorouracil) 
(80). Animal studies, which enabled the investigation of single cytotoxic agents, showed that 
methotrexate, fluorouracil, and cyclophosphamide may cause brain structural alterations such as 
reduced hippocampal cell proliferation and delayed myelin destruction (25, 85-88), and may result 
in learning and memory problems (25, 86, 87, 89, 90). Therefore the late effects of adjuvant CMF 
chemotherapy reported in this thesis may at least partially apply to contemporary regimens.
In addition, because CMF chemotherapy has been the worldwide adjuvant treatment of choice 
for invasive breast cancer for almost 20 years up till the late nineteen nineties (91), a large group 
of breast cancer survivors who have been treated with CMF chemotherapy may experience its 
cognitive sequelae in the near future. Furthermore, most breast cancer patients are diagnosed after 
the age of 60 years (80) and a substantial percentage of these patients may already experience some 
age-related cognitive decline. Any additional adverse cognitive effect induced by chemotherapy, 
even if these effects are small, may therefore be of clinical relevance. Therefore, the results of the 
studies in this thesis apply to a large proportion of the breast cancer survivor community for years 
to come. 
Future research
Contemporary regimens
As CMF chemotherapy is no longer the treatment of choice, future studies should focus on the 
late effects of contemporary regimens, in order to clarify if these regimens are also associated with 
late cognitive functioning and brain structure. The more recent studies showed that the regimens 
that are currently prescribed for the adjuvant treatment of breast cancer are also associated with 
neuro-cognitive dysfunction (55, 92-94). However, because there are several co-existing regimens 
that are currently applied in the treatment of adjuvant breast cancer (80), it will be difficult to gather 
a sufficiently large homogenous group of long-term survivors. Furthermore, because since the late 
nineteen nineties the adjuvant regimen of choice for the treatment of breast cancer has changed 
several times (80), it will take some time before we will be able to study the effects of contemporary 
cytotoxic regimens in patients that have been treated more than 20 years ago, simply because 
these regimens were not available back then. With the addition of neuropsychological assessment 
to trial protocols for new regimens, the acute and long-term effects of cytotoxic treatment can 
be monitored directly and enables the investigation of the potential causal relationship between 
cytotoxic treatment and cognitive dysfunction. 
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Time since treatment
Even though in the studies in the current thesis there was a large range of time since treatment 
among subjects, the cross-sectional design of these studies did not allow me to investigate whether 
the effects of chemotherapy changed with accumulating time since treatment. Follow-up of the 
population under investigation in the current study and in other studies on the long-term effects 
of cytotoxic treatment is needed to identify if the late effects of (CMF) chemotherapy change or 
remain stable at longer times since treatment.
Measurements
For the studies described in this thesis I used reference data that had been collected in the 
framework of the Rotterdam Study (13, 31). To ensure comparability of outcome measures, the 
chemotherapy-exposed breast cancer survivors completed the exact same examinations as the 
participants of the Rotterdam Study, at the same research center and executed by the same 
technicians. Hence, the examinations were not specifically selected to answer our research 
question. Although the Rotterdam Study includes a set of neuropsychological examinations and 
an extensive scan protocol, there are several neuropsychological tests and scan sequences which 
have proved to be sensitive to pick up the effects of chemotherapy that were not part of the study 
protocol of the Rotterdam Study. For example, several neuropsychological studies have identified 
adverse cognitive effects of chemotherapy with tests measuring visual memory, mental flexibility 
and working memory (82, 95-98). Furthermore, a recent study by our group in which functional 
MRI was used reported long-term general and cognitive task-specific hypo-activation of brain areas 
in chemotherapy-exposed breast cancer survivors compared to breast cancer survivors that only 
received local therapy (56). In addition, the Rotterdam Study does not implement an extensive 
and validated questionnaire on subjective cognitive functioning. Even though there is no strong 
correlation between subjective cognitive complaints and objective cognitive functioning (7, 37), self-
reported cognitive complaints are important indications of quality of life that add to the information 
obtained from neuropsychological tests. 
By implementing a neuropsychological test battery that is focused on cognitive problems that are 
frequently observed in chemotherapy-exposed breast cancer survivors, and by adding a sequence 
for fMRI to the study protocol, future studies on the long-term effects of chemotherapy might pick 
up larger and/or unidentified late effects of cytotoxic treatment. 
Genetic analysis
Several candidate genes have been suggested that may be involved in the effect of cytotoxic 
treatment on cognitive functioning (22). Currently a number of studies on genetic determinants for 
chemotherapy-induced cognitive decline are being conducted (99, 100). Preliminary results of these 
studies show that chemotherapy-exposed patients who are homozygous for the minor allele of the 
MRE11A gene, or who have at least one Val allele of the Catechol-O-Methyltransferase (COMT) 
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gene, score lower on neuropsychological tests compared to non-chemotherapy-exposed patients 
or healthy control subjects. These findings could guide future studies on genetic factors that can 
increase the risk for chemotherapy-induced cognitive change.
Reference population
For the studies in this thesis I sampled reference subjects from the Rotterdam Study; an ongoing 
population-based prospective cohort study. By comparing the breast cancer patients to these 
reference subjects I was able to study the absolute differences in cognitive functioning and brain 
structure between the general population and long-term chemotherapy-exposed breast cancer 
survivors. However, by not including a reference group of breast cancer survivors that only received 
local therapy I was not able to distinguish the effects of chemotherapy and of cancer itself. Although 
prospective cognitive studies have showed that independently from cancer, chemotherapy is 
associated with cognitive functioning (94, 101, 102), some authors have suggested a direct link 
between cancer and neuro-degeneration (103, 104). 
Adding an additional reference group of long-term survivors who had only received local therapy 
(i.e. surgery with or without radiotherapy), may untie the cognitive consequences of a mere history 
of cancer and the exposure to cancer therapies and may contribute to the understanding of unique 
or shared mechanisms that cause these cognitive consequences. 
Population-based perspectives
Most studies that have been conducted so far had only small sample sizes which limits both 
the power in the study and the potential to investigate underlying mechanisms in more detail. 
Investigators should take advantage of the possibilities to participate in currently ongoing large 
cohort studies to study the chemotherapy-induced brain alterations and cognitive dysfunction and 
their underlying mechanisms. The Nurses’ Health Study (105-107) for example is a prospective 
population-based cohort study among more than 100,000 women who have been followed over 
decades. Such a setting offers a huge potential to investigate late effects of cytotoxic treatments in 
cancer patients. With investigators from the Rotterdam Study (13) we have started to investigate 
the late effects of chemotherapy on brain structure and function in that cohort. Among participants 
of the Rotterdam Study, 792 cancers, including 186 breast cancers, had occurred by the end of 
2004 (108). Of the majority of these patients prospective neuropsychological data is available, and 
for several patients there are MRI scans obtained at baseline (i.e. before the cancer diagnosis). 
Although the cancer survivors within the Rotterdam Study are a heterogeneous group of 
survivors regarding treatment (e.g. chemotherapy yes/no, regimen, dosimetry, hormonal therapy, 
radiotherapy) and cancer stage, in contrary to the breast cancer survivors in my studies, the 
Rotterdam Study offers the opportunity to prospectively investigate the adverse cognitive effects 
of adjuvant cytotoxic treatment, if necessary stratified by cancer type, and with the possibility to 
sample various reference groups including patients who only received local therapy and cancer-
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free subjects. The current follow-up of MRI examinations in the Rotterdam Scan Study will ensure 
the longitudinal analysis of the effects of cytotoxic treatment on brain volume, white matter lesion 
volume, white matter microstructural integrity and cerebral blood flow (31).
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Summary
Chapter 1 introduces the background and aim of this thesis. Adjuvant chemotherapy is widely 
used in the treatment of breast cancer. One of its adverse effects that has gained more attention 
over the last years are cognitive dysfunction and brain structural alterations, which have been 
observed shortly up till several years after treatment. Not much is known about the long-term 
cerebral consequences of adjuvant chemotherapy. However, as the number of long-term survivors 
is increasing this topic is gaining more interest. Therefore, the objective of this study was to 
investigate the late effects of adjuvant cytotoxic treatment for breast cancer on brain function and 
structure. In order to do this we compared almost 200 breast cancer patients aged 50 to 80 years 
who had been treated with CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil) chemotherapy 
on average more than 20 years before, to a large set of at least twice as much women without a 
history of cancer from the Rotterdam Study; an ongoing prospective population-based cohort study. 
We studied cognitive functioning, brain tissue volume, cerebral white matter integrity, cerebral 
blood flow, and the prevalence of carotid artery plaques and incidental findings on brain MRI.
Chapter 2 gives an overview of the literature on the long-term effects of adjuvant chemotherapy 
on cognitive functioning, brain structural and functional alterations, and the risk of dementia. 
Previous studies showed that chemotherapy is associated with long-term subtle cognitive 
dysfunction in some, but not all patients. The effects were mainly observed in the domains of 
verbal memory and executive functioning. The only three neuroimaging studies in patients that 
were five or more years post-treatment show that cytotoxic treatment is associated with less long-
term focal gray matter volume, worse global and focal white matter integrity, and hypo-activation 
of brain areas during cognitive tasks. The four studies conducted so far on the risk of dementia 
following chemotherapy showed no increased risk for dementia following cytotoxic treatment, 
yet had severe methodological limitations and cannot be considered as conclusive. The results 
from this review suggest that five or more years after cessation of treatment, various regimens of 
adjuvant chemotherapy are associated with impaired cognitive functioning possibly as a result of 
chemotherapy-induced structural brain changes.
In Chapter 3 we compared the neuropsychological tests scores of the chemotherapy-
exposed patients and the population-based reference subjects. The patients performed worse 
than reference subjects on neuropsychological tests of immediate and delayed verbal memory, 
processing speed, executive functioning and psycho-motor speed. Also on a summary measure 
of the neuropsychological test results that allowed for mutual correlation, the reference group 
significantly outperformed the breast cancer survivors. In addition, the chemotherapy-exposed 
survivors reported memory complaints more often. There were no differences between groups 
in the mean score on the mini mental state examination: a dementia screenings list. These results 
show that chemotherapy for breast cancer is associated with cognitive problems and memory 
complaints, but not with an increased prevalence of dementia.
The mechanisms by which chemotherapy may induce cognitive dysfunction are currently 
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under intensive investigation. One of the proposed mechanisms is direct neurotoxicity. As both 
methotrexate and 5-fluorouracil have proven to be able to cross the blood brain barrier in low 
doses, they may induce long-lasting brain structural alterations. 
To investigate if adjuvant chemotherapy is associated with long-term brain structure we compared 
the group of chemotherapy-exposed survivors to the population-based reference subjects on 
several neuroimaging outcome measures, including total brain volume, total gray and white matter 
volume, focal gray matter volume, global and focal white matter microstructural integrity, and 
cerebral blood flow (Chapter 4). In Chapter 4.1 we reported that CMF chemotherapy-exposed 
breast cancer survivors had less total brain tissue volume and less gray mater volume than the 
population based reference subjects. No group differences were observed in focal gray mater 
volume. The results did not change after correcting for potential confounders such as age, height, 
cardiovascular risk factors, symptoms of depression, and education level. 
In addition to brain atrophy, cytotoxic treatment may also induce cerebral white matter 
microstructural damage. The latter can be characterized using diffusion tensor imaging (DTI), 
which visualizes the extent and directionality of the diffusion of water molecules within brain tissue. 
Generally, water diffusion in healthy white matter fiber bundles is highly anisotropic, as it is hindered 
by tissue architecture and therefore more prominent along the fiber direction. Increased diffusivity 
is often interpreted as being related to myelin damage, demyelination or axonal injury. In Chapter 
4.2 we showed that longer time since adjuvant CMF chemotherapy is associated with worse global 
and focal white matter microstructural integrity. We did not observe group differences in white 
matter integrity. A possible explanation for these results is that the group of chemotherapy-exposed 
cancer survivors was healthier and therefore had better white matter integrity at baseline than the 
reference group. This idea is supported by the fact that the breast cancer patients were taller, and 
were better educated than the reference subjects. 
As stated, our understanding of the potential mechanisms underlying chemotherapy-induced 
brain structural changes is still limited. Since reductions in total cerebral blood flow have been 
associated with gray matter atrophy, we considered that the difference in cerebral gray matter 
volume that we observed between chemotherapy-exposed breast cancer survivors and reference 
subjects (see Chapter 4.1) might be due to chemotherapy-induced differences in cerebral blood 
flow. Flow deficits could be related to vascular damage, which is why we subsequently looked at the 
prevalence of carotid artery plaques. As cerebral blood flow is closely related to brain volume, we 
also looked at brain perfusion, defined as total cerebral blood flow divided by brain volume (× 100). 
In Chapter 4.3 we showed that there were no differences between chemotherapy-exposed breast 
cancer survivors and reference subjects regarding cerebral blood flow, perfusion or prevalence of 
carotid plaques. This indicates that neither can explain the effects of CMF chemotherapy on gray 
matter volume that we observed.
An implication of the use of neuroimaging is the chance of discovering incidental findings, 
defined as previously undetected abnormalities of potential clinical relevance that are unexpectedly 
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discovered and are unrelated to the purpose of the specific outcome measures under study. Whether 
the prevalence of such abnormalities in cancer patients is similar to that in the general population 
is unclear. The brain scans of all participants of our studies were reviewed for incidental findings 
according to a predefined protocol. In Chapter 5 we reported that within the chemotherapy-
exposed breast cancer survivors three types of intracranial incidental findings were observed; 
aneurysms, meningiomas, and pituitary macro adenomas. The age-adjusted prevalence of only 
the pituitary macro adenomas was higher in the breast cancer survivors than in the population-
based sample. 
In Chapter 6, the most important conclusions and implications of the current research is 
discussed and summarized. Adjuvant CMF chemotherapy given for breast cancer is associated 
with long-term worse cognitive functioning, less total gray matter volume, and worse white matter 
microstructural integrity, but not with total cerebral blood flow, cerebral perfusion, or plaques in 
the carotid artery. By comparing chemotherapy-exposed breast cancer survivors to a reference 
population without a history of cancer it is not possible to distinguish the effects of chemotherapy 
and cancer itself. Our findings suggest that chemotherapy-induced gray matter volume reductions 
and worse white matter microstructural integrity may be part of the mechanisms underlying the 
observed long-term cognitive dysfunction. We did not observe differences in cerebral perfusion 
between the chemotherapy-exposed survivors and the reference group and therefore it is unlikely 
that chemotherapy-induced altered cerebral perfusion is causing the observed brain structural 
differences nor is it responsible for the differences in cognitive functioning or brain structure 
between the groups. 
The absence of group differences on a dementia screener suggests that adjuvant CMF 
chemotherapy does not lead to an accelerated incidence or increased risk of dementia, at least not 
within the age range covered in this study. 
Because even mild cognitive dysfunction is associated with lower quality of life, this outcome 
is important considering the large and still increasing number of breast cancer survivors. The 
studies in this thesis are the first that investigate the very late effects of chemotherapy on cognitive 
functioning. These results need replication it is justified to inform patients timely about long-term 
cognitive consequences of adjuvant cytotoxic treatment. This research therefore should not yet be 
considered by patients at the moment they have to decide whether or not to undergo chemotherapy. 
However, it should stimulate clinicians to be perceptive of cognitive problems in patients with a 
history of adjuvant CMF chemotherapy for breast cancer. 
Nowadays, CMF chemotherapy is not the main choice of adjuvant therapy for invasive breast 
cancer anymore. Whether contemporary regimens are also associated with long-term brain 
structural and functional alterations, and whether these effects are similar the late effects of 
adjuvant CMF chemotherapy I observed is largely unknown. However, as animal studies show that 
cyclophosphamide and 5-fluorouracil, agents that are still widely used in contemporary regimens, 
are both independently associated with cognitive problems and brain structural alterations, it is 
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not unlikely that contemporary regimens are also associated with long-term cognitive dysfunction. 
The cognitive problems and brain structural alterations that have been observed in breast cancer 
patients treated with contemporary regimens at 10 years post-treatment add to this idea.
Furthermore, CMF chemotherapy has been the worldwide adjuvant treatment of choice for 
invasive breast cancer for almost 20 years up till the late nineteen nineties, a large group of breast 
cancer survivors who have been treated with CMF chemotherapy may experience its cognitive 
sequelae in the near future. In addition, as most breast cancer patients are diagnosed after the 
age of 60, a substantial percentage of these patients may already experience some age-related 
cognitive decline. Even small additional adverse cognitive effect induced by chemotherapy may 
thus be of clinical relevance. Therefore, the results of the studies in this thesis apply to a large 
proportion of the breast cancer survivor community for years to come.
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Samenvatting
Chemotherapie is een veel gebruikte aanvullende behandeling na radiotherapie en chirurgie 
voor borstkanker. Bijwerkingen van chemotherapie waar de laatste jaren in toenemende mate 
aandacht aan wordt besteed zijn cognitieve achteruitgang en structurele veranderingen van het 
brein. Van beiden weten we inmiddels dat zij tot enkele jaren na de behandeling kunnen optreden. 
Of deze bijwerkingen ook op de lange termijn aanhouden is nog grotendeels onbekend. Doordat het 
aantal borstkanker patiënten dat lang na de diagnose nog in leven is  gestaag toeneemt, is er meer 
aandacht gekomen voor de kwaliteit van leven –en daarmee het cognitief functioneren– van deze 
lange overlevers. Het doel van het onderzoek beschreven in dit proefschrift was dan ook inzicht te 
krijgen in de late effecten van adjuvante chemotherapie voor borstkanker op het functioneren   en 
de structuur van het brein. Wij  vergeleken bijna 200 voormalige borstkankerpatiënten tussen de 50 
en 80 jaar oud die gemiddeld meer dan 20 jaar eerder werden behandeld met CMF (Cyclofosfamide, 
Methotrexaat, 5-Flurouracil) chemotherapie, met minimaal twee keer zoveel deelneemsters van 
ERGO (Erasmus Rotterdam Gezondheids Onderzoek; een prospectieve populatie studie) die nooit 
kanker hadden gehad. We bestudeerden het effect van chemotherapie op cognitieve functies, brein 
volume, cerebrale witte stof integriteit, hersendoorbloeding en de prevalentie van plaques in de 
carotiden. Ook keken wij naar toevalsbevindingen op MRI scans van de hersenen. 
 In Hoofdstuk 2 wordt besproken wat er tot nu toe bekend is over de late effecten van 
chemotherapie wat betreft cognitief functioneren, de structuur van de hersenen en het risico 
op dementie bij kankerpatiënten behandeld met chemotherapie. Vijf voorgaande studies laten 
zien dat chemotherapie op de lange termijn is geassocieerd met cognitief disfunctioneren in 
een subgroep van patiënten. De meeste problemen worden gezien bij het verbaal geheugen en 
executief functioneren. De enige drie gepubliceerde beeldvormende studies naar de relatie van 
chemotherapie en de structuur van het brein laten zien dat vijf- of meer jaar na de behandeling, 
chemotherapie gerelateerd is aan minder focale grijze stof volume, slechtere globale en focale witte 
stof integriteit, en hypoactivatie van breingebieden tijdens het uitvoeren van cognitieve taken. De 
tot nu toe vier studies die de relatie onderzochten tussen chemotherapie en dementie vonden geen 
aanwijzingen voor een verband. Echter, door de methodologische beperkingen van deze studies 
moeten de resultaten met voorzichtigheid worden geïnterpreteerd.  
In Hoofdstuk 3 vergelijken we de neuropsychologische testscores van de borstkanker 
overlevers met die van de deelneemsters aan het ERGO onderzoek. De patiëntgroep presteerde 
significant slechter op tests die een beroep doen op direct en uitgesteld verbaal geheugen, 
verwerkingssnelheid, executief functioneren en psycho-motore snelheid, als ook op een 
samenvattende maat voor cognitief functioneren. Tevens rapporteerden de borstkankerpatiënten 
vaker geheugenproblemen dan de referentiegroep. Gemiddelde scores op een screeningslijst voor 
dementie verschilden niet tussen de twee groepen. De resultaten van dit onderzoek laten zien 
dat chemotherapie geassocieerd is met cognitieve problemen en klachten, maar niet met een 
verhoogd risico op dementie.
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De mechanismen waardoor chemotherapie leidt tot cognitief disfunctioneren worden momenteel 
intensief onderzocht. Eén van de mechanismen is dat chemotherapie een direct neurotoxisch 
effect kan hebben op de cellen van het centrale zenuwstelsel. Aangezien zowel methotrexaat als 
5-fluorouracil de bloed-hersen barrière kunnen passeren, in lage doseringen, is het mogelijk dat zij 
kunnen leiden tot langdurige structurele veranderingen van het brein.  
Om te onderzoeken of adjuvante chemotherapie inderdaad geassocieerd is met de structuur 
van het brein op de lange termijn vergeleken wij de  borstkankerpatiënten behandeld met 
chemotherapie met de eerder gedefinieerde referentie groep op totaal brein volume totaal witte en 
grijze stof volume, focaal grijze stof volume, focale en globale microstructurele witte stof integriteit 
en cerebrale doorbloeding (Hoofdstuk 4). 
In Hoofdstuk 4.1 rapporteerden wij dat het brein van borstkankerpatiënten die chemotherapie 
hadden ondergaan kleiner was dan dat van de referentie groep, en dat dit verschil grotendeels 
te wijten was aan het kleinere grijze stof volume van de groep overlevers. Focaal vonden wij 
geen verschillen in het volume van grijze stof. Deze bevindingen veranderden niet nadat we 
corrigeerden voor factoren die van invloed zouden kunnen zijn op breinvolume, zoals leeftijd, 
lengte, cardiovasculaire risicofactoren, symptomen van depressie en opleidingsniveau.
 Naast volume afname leidt chemotherapie op de lange termijn mogelijk ook tot achteruitgang 
van de witte stof op microstructureel niveau. Dit laatste kan gemeten worden met behulp van diffusie 
tensor beeldvorming (DTI), waarmee de mate en richting van diffusie van water moleculen in het 
brein kan worden geregistreerd. In het algemeen is de diffusie van water in de witte stof anisotroop 
doordat het gehinderd wordt door de verzelstructuur van de witte stof: de diffusie is sterker in de 
richting van de vezels dan loodrecht er op. Een toename van diffusie wordt vaak geïnterpreteerd 
als myeline schade, demyelinisatie of axonale schade. In Hoofdstuk 4.2 lieten we zien dat tijd 
sinds behandeling negatief gecorreleerd is met globale en focale witte stof integriteit. Wij vonden 
geen verschillen tussen de borstkankeroverlevers die chemotherapie hadden ondergaan en de 
referentie groep wat betreft de microstructuur van de witte stof. Een mogelijke verklaring voor deze 
bevindingen is dat de overlevers gezonder waren op het moment dat zij werden gediagnostiseerd 
met borstkanker dan de referentiepopulatie op dat moment, waardoor de integriteit van de witte 
stof van de overlevers initieel beter was. Dit idee wordt ondersteund door het feit dat de groep 
overlevers langer waren en hoger waren opgeleid dan de referentiegroep. 
Zoals eerder gezegd is ons begrip van de potentiele mechanismen die verantwoordelijk zijn 
voor de relatie tussen chemotherapie en structurele veranderingen van het brein nog beperkt. 
Aangezien een afname van cerebrale doorbloeding geassocieerd is met grijze stof atrofie 
onderzochten wij of adjuvante CMF chemotherapie een effect heeft op de doorbloeding van de 
hersenen (zie Hoofdstuk 4.1). Omdat verminderde doorbloeding samenhangt met vasculaire 
schade hebben we tevens gekeken naar de prevalentie van plaques in de carotiden. Aangezien 
totale hersendoorbloeding erg afhankelijk is van het hersenvolume hebben we gekeken naar het 
effect van chemotherapie op cerebrale perfusie (totale hersendoorbloeding / brein volume × 100). 
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In Hoofdstuk 4.3 laten we zien dat er geen verschillen zijn tussen de groep borstkankeroverlevers 
en de referentiegroep wat betreft totale hersendoorbloeding, cerebrale perfusie en prevalentie van 
plaques in de carotiden. Dit geeft aan dat geen van deze variabelen een mediërende rol speelt in 
de relatie tussen chemotherapie en het verminderd grijze stof volume die wij eerder observeerden.
Een implicatie van het gebruik van beeldvormend onderzoek is de kans op het doen van 
toevalsbevindingen. Deze worden gedefinieerd als eerder niet gedetecteerde abnormaliteiten die 
potentieel klinisch relevant zijn en onverwacht worden ontdekt bij onderzoek dat niet als doel heeft 
dergelijke uitkomsten te objectiveren. Of de prevalentie van zulke abnormaliteiten vergelijkbaar is 
tussen  borstkankerpatiënten behandeld met chemotherapie en  de normale bevolking, is onduidelijk. 
De hersenscans van alle borstkankerpatiënten die deel hebben genomen aan onze studies werden 
daarom volgens een vooraf opgesteld protocol gescreend op toevalsbevindingen. In Hoofdstuk 
5 rapporteren we dat binnen de groep borstkankeroverlevers er drie soorten toevalsbevindingen 
werden gezien: aneurysmata, meningeomen en macro adenomen van de hypofyse. Alleen de 
leeftijd-geadjusteerde prevalentie van hypofyse macro adenomen bleek significant hoger in de 
borstkankeroverlevers dan in de referentie groep afkomstig uit de populatiestudie. 
In Hoofdstuk 6 worden de belangrijkste conclusies en implicaties van het totale onderzoek 
besproken en samengevat. Adjuvante CMF chemotherapie gegeven voor borstkanker is op de 
lange termijn geassocieerd met slechtere cognitieve functies, minder grijze stof volume en slechtere 
integriteit van de witte stof op microstructureel niveau, maar niet met de doorbloeding van de 
hersenen of de prevalentie van plaques in de carotiden. Doordat wij in dit onderzoek borstkanker 
patiënten die waren behandeld met chemotherapie vergeleken met een groep vrouwen uit de 
gewone populatie die nooit kanker hadden gehad was het onmogelijk om onderscheid te maken 
tussen het effect van chemotherapie en kanker op zich. Onze bevindingen suggereren dat 
verminderd grijze stof volume als gevolg van chemotherapie en de achteruitgang van de witte 
stof integriteit mogelijk ten grondslag liggen aan de cognitieve problemen op lange termijn die wij 
observeerden. Aangezien wij geen verschillen vonden in de doorbloeding van het brein  tussen 
de borstkankeroverlevers en de referentiegroep is het onwaarschijnlijk dat veranderingen in de 
doorbloeding van de hersenen als gevolg van chemotherapie de oorzaak zijn van de door ons 
geobserveerde associatie tussen chemotherapie, de structuur van het brein en het cognitief 
functioneren. De afwezigheid van groepsverschillen wat betreft scores op de mini mental state 
examination, een screeningslijst voor dementie, wijst er op dat adjuvante CMF chemotherapie niet 
leidt tot een verhoogd risico op dementie, tenminste niet bij vrouwen in de leeftijd van 50 tot 80 jaar. 
Aangezien zelfs subtiele cognitieve problemen geassocieerd zijn met een lagere kwaliteit van 
leven zijn onze bevindingen belangrijk voor de grote en toenemende groep borstkankeroverlevers. 
De studies in dit proefschrift zijn de eerste die hebben gekeken naar de zeer late effecten van 
adjuvante chemotherapie en moeten dan ook worden gerepliceerd alvorens het gerechtvaardigd 
is om patiënten vroegtijdig voor te lichten. Dit onderzoek zou dan ook niet moeten leiden tot het 
informeren van patiënten over de mogelijke cognitieve bijwerkingen van chemotherapie op lange 
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termijn in de beslissingsfase voor chemotherapie. Wel zou het clinici aan moeten zetten oplettend 
te zijn op cognitieve problemen bij borstkankeroverlevers met een voorgeschiedenis van adjuvante 
CMF chemotherapie. 
Adjuvante CMF chemotherapie is niet meer de standaard behandeling voor borstkanker en het 
is nog onduidelijk of de hedendaagse cytotoxische therapieën vergelijkbare cognitieve effecten 
op de lange termijn teweeg brengen. Aangezien dierstudies laten zien dat cyclofosfamide en 
5-fluorouracil –componenten die ook in hedendaagse combinatietherapieën zijn geïmplementeerd– 
beiden afzonderlijk zijn geassocieerd met cognitieve problemen en veranderingen in het brein, is 
het niet ondenkbaar dat ook de huidige chemotherapie is geassocieerd met cognitieve problemen 
op de lange termijn. Dat cognitieve problemen en structurele veranderingen in het brein die zijn 
geobserveerd in borstkankeroverlevers die bijna 10 jaar eerder werden behandeld met hedendaagse 
chemotherapie sluit hierbij aan. 
Adjuvante CMF chemotherapie is tot eind jaren negentig veelvuldig gebruikt. Hierdoor zijn er 
nog veel vrouwen die mogelijk de late cognitieve effecten van deze behandeling zullen ervaren. 
De meeste borstkankerpatiënten worden gediagnostiseerd na het zestigste levensjaar, wanneer 
leeftijds-gerelateerde cognitieve achteruitgang mogelijk al een rol speelt. Elke additioneel nadelig 
effect van chemotherapie kan daardoor van klinische relevantie zijn. Mede hierdoor zijn de resultaten 
van dit onderzoek de komende jaren van toepassing op de grote groep borstkankeroverlevers.
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blij dat ik nog zoveel dingen van je heb mogen 
afkijken in deze periode.
De overige leden van de neuro-groep: 
Benjamin Verhaaren, Daniel Bos, Dymph 
Mesker, Elisabeth Devore, Elizabeth Loehrer, 
Evert van Velsen, Hieab Adams, Jory 
Hoogendam, Joyce van den Ende, Kèren 
Zaccai, Meike Vernooij, Mendel Haag, Michiel 
Bos, Renée de Bruijn, Saloua Akoudad, Sjoerd 
Euser, Tom den Heijer en Vincent Verlinden, mijn 
gewaardeerde collega’s van de Epidemiologie 
afdeling, te weten: Abbas Dehghan, Bouwe 
Krijthe, Daan Loth, Eline Rodenburg, Gabriëlle 
Buitendijk, Germaine Verwoert, Karin Hek, 
Lintje Ho, Mariana Selwaness, Mark Eigelsheim, 
Maryam Kavousi, Milad Solouki, Monica 
Czudowska, Quirijn van den Bouwhuijsen, Rikje 
Ruiter, Virginie Verhoeven en Wishal Ramdas, 
en de fijne mensen van de beeldverwerkers 
groep: Fedde van der Lijn, Marius de Groot, 
Renske de Boer, Sandra de Bie en Vera Valkhof 
wil ik van harte bedanken voor de gezelligheid 
tijdens lunches, borrels, en promotiefeestjes.
voor onze kamer, niet alleen vanwege je 
onderzoeksonderwerp, maar juist ook vanwege 
onze gezamenlijke interesses: als Apple-fan-
girl, jaren ‘80 PC junkie en Hagenees hadden we 
veel om over te praten en konden we af en toe 
een trein delen. Ik wens je veel succes met het 
afronden van je onderzoek!
Vele anderen maakten de PSOE voor mij een 
gezellige thuisbasis. Naomi Boekel en Sandra 
van den Broek, jullie begonnen ongeveer rond 
dezelfde tijd met promoveren en waren altijd in 
voor epidemiologische vraagstukken of gewoon 
een praatje. Naomi, bedankt ook voor je immer 
snelle reacties op al mijn vragen omtrent jouw 
onderzoekspopulatie, de geschiedenis van de 
behandeling van het mammacarcinoom, maar 
ook de trips naar de Albert Heijn. Willem, jij bent 
de lijm van de afdeling. Met koekjes en praatjes 
heb je mij en vele anderen op je kamer gelokt 
voor een goed gesprek in een ontspannen sfeer. 
Bedankt daarvoor. Ook Anja van Eggermond, 
Anouk Pijpe, Chantal Lammens, Cherita 
Sombroek, Christien Schilder, Grace Sigharta, 
Hanna van Waart, Harmke Groot, Heleen 
Feenstra, Jacobien Kieffer, Kirsten Douma, 
Mandy Spaan, Marie-José Blom, Marieke van 
Leeuwen, Marijke Wevers, Martijn Verheus, 
Miranda Gerritsma, Rianne van Nimwegen, 
Riejanne Seigers, Saskia Duijts, Saskia Pelders, 
Susanne Rebers en Wim Groen wil ik bedanken 
voor de samenwerking en/of gezelligheid tijdens 
de vrijdagmiddag borrels, uitjes, kerst lunches, 
of zomaar tussendoor.
De keuze voor mijn paranimfen Benjamin Verhaaren en Remi Soleman was een eenvoudige. Ik 
ben blij ben dat jullie naast mij staan op 20 april.
Twee personen die niet mogen ontbreken in dit dankwoord zijn Prof.dr. Robert Schoevers en 
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Prof.dr. Jack Dekker. Zij introduceerden mij in de wetenschap, betrokken mij bij publicaties en 
namen me mee naar congressen en symposia. Hiervoor ben ik ze enorm dankbaar.
Familieleden en vrienden die de afgelopen jaren dan wel geen inhoudelijke rol hebben gespeeld, 
maar die zeker hebben bijgedragen aan het tot stand komen van dit proefschrift en die ik graag 
bij naam zou noemen zijn: Benjamin Verhaaren, Erik van Dongen, Jeroen Altena, Jordi Simons, 
Peter Alles, Remi Soleman, Ricky Booms en Roeland Koppelmans. Bedankt voor jullie interesse, 
de afleidende avonden en weekenden, de goede gesprekken en bovenal de gezelligheid! Voor jullie 
allemaal geldt dat we elkaar te weinig zie, maar dat wanneer we afspreken het altijd goed voelt. Ik 
hoop jullie nog velen jaren als vrienden te hebben. Ook de familie en vrienden van Stefanie wil ik 
bedanken voor hun interesse in mijn onderzoek.
René, Anne, Marijn en Imme bedank ik voor hun interesse en vertrouwen. René, het voelt 
goed om iemand te hebben die achter je staat. Pa en Ma, bedankt voor jullie vertrouwen en die 
stimulerende omgeving waarin ik ben opgegroeid. Jullie leerden mij dat met doorzettingsvermogen 
en ordelijkheid er veel te bereiken is. Dit boekje is een beetje voor jullie.
Lieve Stefanie, jij haalt het beste in me boven en laat me dingen vanuit een ander perspectief 
zien. Mijn vrije tijd deel ik het liefst met jou, alhoewel dat zeker de laatste tijd misschien anders leek. 
Jouw reislust brengt me op plekken waar ik anders nooit zou zijn geweest en ik zie er naar uit met 
jou in een nieuw avontuur te duiken in de VS!
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Egmond M, van Venrooij J, Bijpost Y, Nusselder H, van Herrewaarden M, Maksimovic I, Achilles 
A, Dekker J. The Amsterdam Studies of Acute Psychiatry - II (ASAP-II): a comparative study of 
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PhD Portfolio - Summary of PhD training and teaching activities
Name    V. Koppelmans
Erasmus MC Department  Epidemiology
Research School   NIHES
Supervisors   Prof. dr. M.M.B. Breteler,
    Dr. S.B. Schagen
Research Skills
2008-2010 MSc in Clinical Epidemiology, Netherlands Institute for Health Sciences, Erasmus 
University Rotterdam, the Netherlands (including courses on methodology, study 
design, and statistical analysis)
General Academic Skills
2010 Biomedical English Writing and Communication, Erasmus MC, Rotterdam, the 
Netherlands 
In-depth courses
2008 Introduction into clinical and fundamental oncology, Dutch Society for Oncology 
(NVvO)
National and international conferences
2012
2012
2011
2010
2010
2008
2008
International Cancer and Cognition Task Force, Paris, France -
oral presentation: Effects of adjuvant chemotherapy for breast cancer on brain 
structure more than 20 years post-treatment
30e Oncologiedagen voor verpleegkundigen, Ede, the Netherlands -
oral presentation: Cognitive problems after chemotherapy
Human Brain Mapping, Quebec, Canada -
poster presentation: Late effects of chemotherapy on brain functioning in the elderly: 
Incidental findings on brain MRI
Two Faces of Evil: Cancer and Neurodegeneration, Paris, France 
International Cancer and Cognition Task Force, New York, US -
poster presentation: Late effects of chemotherapy on brain functioning in the elderly: 
Incidental findings on brain MRI
International Cancer and Cognition Task Force, Amsterdam, the Netherlands
Research Institute of Diseases in the Elderly symposium, Amsterdam, the 
Netherlands
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Teaching activities
2011
2009-2011
2008-2010
Supervising practicals in Study Design at NIHES, Erasmus MC, Rotterdam, the 
Netherlands
Supervising Master students in writing their thesis:
- Anna de Jong - Thesis title: “Long-term effects of CMF chemotherapy on cognitive 
functioning in breast cancer survivors”
- Kirsten Diek - Thesis title: “Selection bias in a study on long term cognitive effects 
of chemotherapy in breast cancer survivors”
Teaching practicals in epidemiology to 4th year medical students, Erasmus MC, 
Rotterdam, the Netherlands
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